WO2013146814A1 - 吸収性物品 - Google Patents
吸収性物品 Download PDFInfo
- Publication number
- WO2013146814A1 WO2013146814A1 PCT/JP2013/058855 JP2013058855W WO2013146814A1 WO 2013146814 A1 WO2013146814 A1 WO 2013146814A1 JP 2013058855 W JP2013058855 W JP 2013058855W WO 2013146814 A1 WO2013146814 A1 WO 2013146814A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- absorbent article
- chain hydrocarbon
- acid
- blood
- hydrocarbon moiety
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
- A61F13/539—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium characterised by the connection of the absorbent layers with each other or with the outer layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
- A61F13/47—Sanitary towels, incontinence pads or napkins
- A61F13/472—Sanitary towels, incontinence pads or napkins specially adapted for female use
- A61F13/47218—Sanitary towels, incontinence pads or napkins specially adapted for female use with a raised crotch region, e.g. hump
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
- A61F13/47—Sanitary towels, incontinence pads or napkins
- A61F13/4704—Sanitary towels, incontinence pads or napkins having preferential bending zones, e.g. fold lines or grooves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
- A61F13/47—Sanitary towels, incontinence pads or napkins
- A61F13/472—Sanitary towels, incontinence pads or napkins specially adapted for female use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
- A61F13/47—Sanitary towels, incontinence pads or napkins
- A61F13/475—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means
- A61F13/4751—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means the means preventing fluid flow in a transversal direction
- A61F13/4756—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means the means preventing fluid flow in a transversal direction the means consisting of grooves, e.g. channels, depressions or embossments, resulting in a heterogeneous surface level
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers
- A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers
- A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
- A61F13/51104—Topsheet, i.e. the permeable cover or layer facing the skin the top sheet having a three-dimensional cross-section, e.g. corrugations, embossments, recesses or projections
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers
- A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
- A61F13/51104—Topsheet, i.e. the permeable cover or layer facing the skin the top sheet having a three-dimensional cross-section, e.g. corrugations, embossments, recesses or projections
- A61F13/51108—Topsheet, i.e. the permeable cover or layer facing the skin the top sheet having a three-dimensional cross-section, e.g. corrugations, embossments, recesses or projections the top sheet having corrugations or embossments having one axis relatively longer than the other axis, e.g. forming channels or grooves in a longitudinal direction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers
- A61F13/514—Backsheet, i.e. the impermeable cover or layer furthest from the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
- A61F13/534—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
- A61F13/534—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad
- A61F13/535—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad inhomogeneous in the plane of the pad, e.g. core absorbent layers being of different sizes
- A61F13/536—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad inhomogeneous in the plane of the pad, e.g. core absorbent layers being of different sizes having discontinuous areas of compression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/84—Accessories, not otherwise provided for, for absorbent pads
- A61F13/8405—Additives, e.g. for odour, disinfectant or pH control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/15203—Properties of the article, e.g. stiffness or absorbency
- A61F2013/15284—Properties of the article, e.g. stiffness or absorbency characterized by quantifiable properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/15203—Properties of the article, e.g. stiffness or absorbency
- A61F2013/15284—Properties of the article, e.g. stiffness or absorbency characterized by quantifiable properties
- A61F2013/15292—Resistance, i.e. modulus or strength
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/15203—Properties of the article, e.g. stiffness or absorbency
- A61F2013/15284—Properties of the article, e.g. stiffness or absorbency characterized by quantifiable properties
- A61F2013/15406—Basis weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/15203—Properties of the article, e.g. stiffness or absorbency
- A61F2013/15284—Properties of the article, e.g. stiffness or absorbency characterized by quantifiable properties
- A61F2013/15463—Absorbency
Definitions
- the present invention relates to an absorbent article.
- a top sheet has a protrusion having cushioning properties on the skin contact surface for the purpose of fitting to the wearer's body.
- the top sheet has a protrusion on the skin contact surface, so that even when the wearer moves the body, the protrusion is expected to fit the wearer's body and hardly leak. ing.
- Patent Document 1 discloses an absorptivity for the purpose of obtaining an excellent fit and leakage-proof property when the absorbent body is deformed into a curved shape protruding toward the wearer's skin when worn.
- the article is listed.
- the absorbent article described in Patent Document 1 has the following configuration: a liquid-permeable top sheet, a liquid-impermeable back sheet, and a liquid-retaining absorbent interposed between the two sheets.
- the absorbent article is formed substantially vertically long, and the absorbent body has a recess on the surface on the back sheet side in the center in the width direction, and the surface sheet side of the portion located on both sides of the recess
- the groove has a pair of grooves extending in the longitudinal direction, and the recess is formed by reducing the basis weight of the constituent material of the absorbent body from other parts, and the width of the recess is 5 to 30 mm.
- the absorbent body is mainly composed of pulp fibers.
- the absorbent article described in Patent Document 1 since the absorbent body is mainly composed of pulp fibers, when menstrual blood is absorbed at the time of wearing, the volume decreases, and when the compressive force is applied from the width direction, the absorbent is absorbed.
- the absorbent article is deformed into a shape that protrudes excessively toward the wearer's skin, and the absorbent article is distorted.
- the present disclosure deforms following the movement of the wearer's leg both when dry before absorbing menstrual blood and when wet after absorbing menstrual blood and returns to its original shape.
- An object of the present invention is to provide an absorbent article that can be fitted and has excellent fit.
- a liquid-permeable top sheet, a liquid-impermeable back sheet, the liquid-permeable top sheet, and a liquid-impermeable back sheet An absorbent article including an absorbent body between, wherein the absorbent article has a mid-high part protruding in the thickness direction of the absorbent article in the excretory opening contact area, Including a part of the top sheet and a cushion part disposed between the top sheet and the absorbent body, the cushion part having a maximum thickness of 3 to 30 mm, and the absorbent body comprising the absorbent body
- the absorbent article has one or more compressed parts formed by continuously or intermittently pressing the absorbent body in the longitudinal direction of the absorbent article, and the one or more compressed parts serve as the absorbent article.
- the skin contact surface of the top sheet in the width direction It found absorbent article, characterized by forming the folding axis for folding so as to protrude.
- the absorbent article of the present disclosure is deformed following the movement of the wearer's leg both when dry before absorbing menstrual blood and when wet after absorbing menstrual blood. It can return to and is excellent in fit.
- FIG. 1 is a perspective view of an absorbent article according to one of the embodiments of the present disclosure.
- FIG. 2 is a front view of the absorbent article 1 shown in FIG.
- FIG. 3 is a rear view of the absorbent article 1 shown in FIG.
- FIG. 4 is an end view taken along the line XX of FIG.
- FIG. 5 is an end view of the YY end surface of FIG.
- FIG. 6 is a diagram for explaining an example of a pressing portion and a folding shaft formed in the absorbent body.
- FIG. 7 is a cross-sectional view of an absorbent article according to another embodiment of the present invention.
- FIG. 8 is a schematic view showing an example of an apparatus for measuring the compressive force.
- FIG. 8 is a schematic view showing an example of an apparatus for measuring the compressive force.
- FIG. 9 is a diagram illustrating an example of the shape of the cushion portion before being incorporated into the absorbent article.
- FIG. 10 is an electron micrograph of the skin contact surface of the top sheet in a sanitary napkin in which the top sheet contains tri-C2L oil fatty acid glycerides.
- FIG. 11 is a micrograph of menstrual blood with or without a blood modifying agent.
- FIG. 12 is a diagram for explaining a method of measuring surface tension.
- FIG. 1 is a perspective view of an absorbent article according to one of the embodiments of the present disclosure.
- the absorbent article 1 shown in FIG. 1 is a sanitary napkin.
- the right back corresponds to the front of the wearer
- the left front corresponds to the rear of the wearer, but the absorbent article 1 shown in FIG.
- it has a symmetrical shape in the front-rear direction and the left-right symmetry.
- the absorbent article 1 shown in FIG. 1 includes a liquid-permeable top sheet 4, a liquid-impermeable back sheet (not shown), a liquid-permeable top sheet 4 and a liquid-impermeable back sheet. And an absorbent body 7 therebetween.
- FIG. 1 also shows the pressing part 3 and the peeling part 5 fixed to the back sheet.
- the absorbent article 1 shown in FIG. 1 has a middle-high part 2 that protrudes in the thickness direction of the absorbent article 1 in the excretory opening contact area.
- the top sheet 4 has a plurality of ridge groove structures extending in the longitudinal direction on the skin contact surface.
- the boundary is indicated by a solid line.
- a wide region surrounded by two solid lines means a buttock, and a narrow region surrounded by two solid lines means a groove
- a plurality of flanges and a plurality of grooves are alternately arranged in the width direction of the absorbent article 1.
- the direction orthogonal to the longitudinal direction of the absorbent article may be referred to as the “width direction”.
- the “middle / high portion” means a portion including a part of the top sheet and the cushion portion, and in the middle / high portion, the thickness is generally reduced from the top portion toward the outer edge.
- the “central portion” regarding the middle-high portion is preferably 0 to about 50% of the distance from the top of the middle-high portion to the outer edge of the middle-high portion in the front view of the absorbent article as shown in FIG. More preferably, it means 0 to about 40%, and even more preferably 0 to about 30% of the area, and the remaining area means the “periphery” of the middle and high parts.
- FIG. 2 is a front view of the absorbent article 1 shown in FIG. 1 and is a view observed from the skin contact surface side of the top sheet 4.
- the upper side corresponds to the front of the wearer and the lower side corresponds to the rear of the wearer.
- the absorbent article 1 shown in FIG. 2 includes a liquid-permeable top sheet 4, a liquid-impermeable back sheet (not shown), a liquid-permeable top sheet 4 and a liquid-impermeable back sheet. And an absorbent body 7 therebetween.
- the absorbent article 1 shown in FIG. 2 also has a middle-high part 2 projecting in the thickness direction of the absorbent article 1 in the excretory opening contact area, particularly in the labia contact area.
- the middle-high part 2 includes a part of the top sheet 4 and a cushion part 6 disposed between the top sheet 4 and the absorber 7.
- FIG. 2 also shows the pressing part 3 and the peeling part 5 fixed to the back sheet.
- FIG. 3 is a rear view of the absorbent article 1 shown in FIG. 1 and is a view observed from the clothing contact surface side of the back sheet 8.
- the upper side corresponds to the front of the wearer and the lower side corresponds to the rear of the wearer.
- the fixing portion 9 is coated on the clothing contact surface of the liquid-impermeable back sheet 8, and the peeling portion 5 is temporarily fixed to the fixing portion 9. .
- a wearer can peel the peeling part 5 from the fixing
- FIG. 4 is an end view taken along the line XX in FIG.
- a liquid-impermeable back sheet 8 an absorbent body 7, and a liquid-permeable top sheet 4 are laminated in order from the bottom, and in the excretory opening contact area, the cushion portion 6 is disposed between the absorber 7 and the liquid-permeable top sheet 4.
- the middle-high part 2 includes a part of the top sheet 4 and the cushion part 6, and the absorbent article 1 is more specifically near the outer edge of the cushion part 6.
- the absorbent article 1 shown in FIG. 4 has a plurality of squeezed portions 13 formed by intermittently squeezing the absorbent body 7 in the longitudinal direction of the absorbent article 1, and a plurality of squeezed parts.
- the portion 13 forms a folding shaft 14 for folding the absorbent article 1 in the width direction so that the skin contact surface of the top sheet 4 protrudes.
- bending the absorbent article from the folding axis so that the skin contact surface of the top sheet protrudes in the width direction may be referred to as “convex deformation”.
- the state is sometimes referred to as “convex deformation”.
- the cushion part 6 is formed from an air-through nonwoven fabric and has a maximum thickness of about 15 mm.
- the density of the cushion portion 6 in the outer peripheral portion 12 is higher than the density of the cushion portion 6 in the central portion 11.
- FIG. 5 is an end view of the YY end face of FIG.
- the absorbent article 1 shown in FIG. 5 has the pressing part 3 formed by pressing the top sheet 4 and the absorber 7 in the vicinity of the outer edge of the cushion part 6, more specifically, outside the cushion part 6.
- the top sheet 4 has a plurality of groove structures on its skin contact surface.
- the absorbent article 1 shown in FIG. 5 has a plurality of pressing parts 13 formed by pressing the absorbent body 7, which are arranged in the longitudinal direction of the absorbent article 1, and the plurality of pressing parts 13. However, the folding shaft 14 for convexly deforming the absorbent article 1 is formed.
- the density of the cushion portion 6 in the outer peripheral portion 12 is higher than the density of the cushion portion 6 in the central portion 11.
- FIG. 5 shows the elastic member 15.
- the density of the cushion portion 6 in the outer peripheral portion 12 is higher than the density of the cushion portion 6 in the central portion 11.
- the density of the cushion part in the outer peripheral part is the same as the density of the cushion part in the central part, and in the absorbent article of still another embodiment of the present disclosure, the density of the cushion part in the outer peripheral part is The density is lower than the density of the cushion part in the central part.
- the cushion part is not particularly limited, and preferably includes a nonwoven fabric in which the intersections of the fibers are heat-sealed.
- a nonwoven fabric in which the intersection of each fiber is heat-sealed the thing containing a natural fiber, a chemical fiber, or both is mentioned, for example. Since the intersection of each fiber is heat-sealed, the absorbent article of the present disclosure starts from the folding axis, both when dry before absorbing menstrual blood and when wet after absorbing menstrual blood. It is possible to quickly return to the original shape from the bent state. Further, even after menstrual blood is absorbed, the cushion portion, and thus the middle-high portion, can be excellent in shape stability.
- the non-woven fabric in which the intersections of the fibers are heat-sealed preferably contains about 50 to about 100% by weight of thermoplastic chemical fiber and more preferably about 70 to about 100% for heat-sealing each fiber. Including mass%.
- the raw material of the thermoplastic chemical fiber include polyethylene (PE), polypropylene (PP), polyethylene terephthalate (PET), PE and PP graft polymers, and examples of the fiber type of the thermoplastic chemical fiber. , Single fibers, composite fibers, heat-shrinkable fibers, heat-extensible fibers, atypical fibers, three-dimensional crimped fibers, split fibers, and the like.
- the thermoplastic chemical fiber may be a fiber containing a hydrophilic agent, a water repellent or the like, or a fiber coated with them. it can.
- the thermoplastic chemical fiber may be a fiber that has been hydrophilized by corona treatment, plasma treatment, or the like.
- the fiber in order to improve the whitening property of the cushion part, can contain an inorganic filler such as titanium oxide, barium sulfate, calcium carbonate or the like.
- an inorganic filler such as titanium oxide, barium sulfate, calcium carbonate or the like.
- the fiber constituting the cushion part is preferably a composite fiber rather than a single fiber, and more preferably a core-sheath type composite fiber containing polyethylene in the sheath part in consideration of compression recovery.
- compression recoverability is a characteristic that indicates that the middle and high parts continue to contact the excretion port having a complex shape, and represents the recoverability from the convex deformation of the absorbent article. This is different from the characteristic “compression force”.
- the composite fiber examples include a core-sheath type composite fiber in which the melting point of the core component is higher than the melting point of the sheath component, for example, an eccentric type core-sheath type composite fiber, and a side-by-side type composite fiber having two different melting points.
- examples of the atypical fiber include atypical fibers such as a hollow type, a flat type, a Y type, and a C type
- examples of the three-dimensional crimped fiber include a three-dimensional crimped fiber such as a latent crimp and an actual crimp.
- the split fibers include split fibers that are split by a physical load such as water flow, heat, and embossing. The above fibers preferably have a fineness of about 1.1 to about 8.8 dtex in consideration of ease of menstrual blood and the like, and touch.
- Examples of the natural fiber include cellulose such as pulverized pulp, cotton, etc., regenerated cellulose such as rayon and fibril rayon, semi-synthetic cellulose such as acetate and triacetate, and any combination thereof. In view of cost and formability, pulverized pulp is preferable.
- the cushion part When the cushion part contains the above-mentioned cellulose, regenerated cellulose and / or semi-synthetic cellulose, it can draw menstrual blood and suppress leakage of menstrual blood in a state where body pressure is difficult to be applied to the middle and high parts such as sleeping posture. it can. If the cushion part is a nonwoven fabric made of a chemical fiber, for example, 100% thermoplastic chemical fiber, menstrual blood may flow on the outermost surface of the top sheet, causing leakage.
- a chemical fiber for example, 100% thermoplastic chemical fiber
- the cushion portion can be formed by web forming, for example, a dry method (card method, spunbond method, melt blown method, airlaid method, TOW, etc.), a wet method, or a combination thereof.
- a dry method card method, spunbond method, melt blown method, airlaid method, TOW, etc.
- a wet method or a combination thereof.
- the method for bonding the cushion portion include thermal bonding, needle punching, chemical bonding, and hydroentanglement method.
- the cushion part is not particularly limited.
- an air-through nonwoven fabric for example, an air-through nonwoven fabric, a point bond nonwoven fabric, a spunbond nonwoven fabric, a spunbond / meltblown / spunbond nonwoven fabric (SMS nonwoven fabric), and a thermal fusion where each fiber intersection is thermally fused.
- SMS nonwoven fabric spunbond / meltblown / spunbond nonwoven fabric
- thermal fusion where each fiber intersection is thermally fused.
- a spunlace nonwoven fabric having intersections and more preferably an air-through nonwoven fabric. This is because the air-through nonwoven fabric is bulky, has a low density, and is excellent in the touch.
- the cushion portion has a maximum thickness of about 3 to about 30 mm, preferably has a maximum thickness of about 4 to about 20 mm, and more preferably about 5 to about 10 mm. Has maximum thickness.
- the absorbent article may be convexly deformed when compression in the width direction is not applied to the absorbent article, and the repulsive force of the cushion portion is small and convex. It may be difficult to return the deformed absorbent article to its original shape.
- the maximum thickness is larger than about 30 mm, the repulsive force of the cushion portion is excessively large, the absorbent article is difficult to be convexly deformed, and when the wearer closes the leg, it bends from a point other than the folding axis. There is a case.
- the maximum thickness of the said cushion part when the maximum thickness of the said cushion part exists in the said range, it can fit a wearer's excretion opening
- the maximum thickness of the said cushion part means not the cushion part taken out from the absorbent article but the maximum thickness of the cushion part in the state of an absorbent article.
- the folding shaft 14 is formed from a plurality of compressed portions 13, but the absorbent article according to the present disclosure compresses the absorbent body continuously or intermittently in the longitudinal direction of the absorbent article. It has one or a plurality of pressing parts formed by doing, and the one or a plurality of pressing parts form a fold axis for convexly deforming an absorptive article.
- FIG. 6 the example of the pressing part and folding axis
- FIGS. 6A to 6C are diagrams for explaining an example of a pressing portion and a folding shaft formed in the absorbent body.
- FIGS. 6A to 6C are views of the absorber 7 as viewed from the back sheet side.
- the right side corresponds to the front of the wearer and the left side corresponds to the rear of the wearer.
- the absorber 7 has the some pressing part 13 formed by squeezing the absorber 7 in the longitudinal direction, and the some pressing part 13 has the folding shaft 14 in it. Forming. Moreover, in Fig.6 (a), the pressing part 13 is a rhombus and is continuing. Furthermore, in FIG. 6A, the plurality of pressing parts 13 are arranged in the center part in the width direction of the absorbent body 7.
- the absorber 7 has the some pressing part 13 formed by squeezing the absorber 7 in the longitudinal direction, and the some pressing part 13 has the folding shaft 14 in it.
- Forming. 6 (b) is different from FIG. 6 (a) in that a set of three continuous rhombus pressing parts 13 are arranged with a certain interval.
- the absorber 7 has the some pressing part 13 formed by squeezing the absorber 7 in the longitudinal direction, and the some pressing part 13 has the folding shaft 14 in it. Forming.
- the pressing part 13 is a rhombus and is continuing, the point by which the pressing part 13 is formed only in the range which overlaps with the cushion part 6 in thickness direction is FIG. ) Is different.
- the squeezed portion 13 is disposed in the entire longitudinal direction of the absorbent body 7. It is because it can follow the concave shape of a wearer's pubis and the convex groove
- the pressing part which forms a folding axis is formed in the center part of the width direction of an absorber. This is because the folding shaft is formed at the center portion in the width direction of the absorbent article, and the absorbent article can be convexly deformed so that the center portion in the width direction becomes the top portion.
- the squeezing part that forms the folding shaft can be formed by a method known in the art, for example, a pair of upper and lower embossing rolls having a squeezing pattern formed on one side and below the melting point of the fiber.
- the squeezed portion can be formed by squeezing at a temperature of about 100 to about 1000 N / cm.
- the shape of the pressing part that forms the folding axis is not particularly limited, and examples thereof include patterns such as a round shape, a rhombus shape, a rectangular shape, and an oval shape.
- the compressed portion preferably has a longitudinal length and width of the absorbent article of about 0.2 to about 5 mm, more preferably about 0.5 to about 3 mm, and more preferably about 0.7 to about 2 mm. Has a length in the direction. When the length is less than about 0.2 mm, it is difficult to form a starting point that causes the absorbent article to be convexly deformed. When the said length exceeds about 5 mm, when the compression of the width direction is not applied to the absorbent article, the absorbent article may be convexly deformed.
- FIG. 7 is a cross-sectional view of an absorbent article according to another embodiment of the present invention.
- FIG. 7 is an end view corresponding to the YY end surface of FIG. 2, and the thickness direction of the absorbent article is enlarged to help understanding.
- the absorbent article 1 shown in FIG. 7 has the pressing part 3 formed by pressing the top sheet 4 and the absorber 7 in the vicinity of the outer edge of the cushion part 6, more specifically, outside the cushion part 6. .
- the absorbent article 1 shown by FIG. 7 has the some pressing part 13 formed by squeezing the absorber 7 in the longitudinal direction of the absorbent article 1, and the some pressing part 13 is.
- the folding shaft 14 for convexly deforming the absorbent article 1 is formed.
- the absorbent body 7 has a groove portion 16 along the folding shaft 14 on the backsheet 8 side, and the backsheet 8 is recessed along the groove portion 16. When the back sheet is recessed along the groove portion of the absorbent body, the absorbent article is more easily deformed in a convex shape.
- the absorbent article 1 as shown in FIG. 7 can be manufactured as follows, for example.
- a back sheet is pasted on a laminate composed of a top sheet, a cushion portion, and an absorbent body having a groove along the folding axis
- the back sheet to be laminated while being conveyed in the longitudinal direction is laminated on the laminate by lowering the line tension, so that the back sheet can be recessed along the groove portion of the absorber.
- the said laminated body is adhere
- the back sheet can be depressed along the groove portion of the absorber by transporting the laminate on the support and laminating the back sheet on the laminate while sucking air from the support side. .
- the disk-like shape is formed along the groove part from the back sheet.
- the back sheet can be recessed along the groove of the absorber.
- a folding axis of the absorbent body can be formed and the back sheet can be recessed along the groove portion of the absorbent body.
- the absorbent article of the present disclosure deforms following the movement of the wearer's leg both when dry before absorbing menstrual blood and when wet after absorbing menstrual blood, and has an original shape
- the reason why the fitting property is high can be described with reference to FIG. 7 as appropriate.
- the absorbent article of the present disclosure since the absorbent body has a folding axis, when the wearer is compressed from the width direction, such as when the wearer closes the leg, the absorbent article starts from the folding axis. It can be bent so that the skin contact surface of the top sheet protrudes in the width direction of the article.
- the absorbent article 1 is lifted in the direction of the arrow U with the folding shaft 14 as a starting point, and the cross section of the absorbent article 1 is deformed into a convex shape.
- the absorbent article 1 has the cushion part 6, the cross section is hard to deform
- the absorbent article When compression from the width direction of the absorbent article is lost, such as when the wearer opens his / her leg, it has a maximum thickness of 3 to 30 mm, and the intersection of each fiber is heat-sealed as desired. Since the absorbent article can quickly return to its original shape due to the repulsive force of the cushion part including the nonwoven fabric, it has excellent fit. Moreover, since it is excellent in fit property, it is hard to produce a clearance gap between a wearer's body and an absorbent article, and menstrual blood does not leak easily.
- the cushion part includes a nonwoven fabric in which the intersections of the respective fibers are heat-sealed as desired, and not only when dry before absorbing menstrual blood but also after wet absorption of menstrual blood Even at times, the repulsive force can be maintained and the above-described action can be exhibited.
- the cushion portion preferably has an average basis weight of about 50 to about 800 g / m 2 , more preferably about 100 to 500 g / m 2 , and even more preferably about 150 to about 300 g / m 2 .
- the cushion portion has an average basis weight in the above range, even when wet after absorbing menstrual blood, the mid-high portion does not collapse, and the mid-high portion fits the excretory mouth of the wearer, particularly the labia, Leakage can be reduced.
- the “average basis weight” means the basis weight of the entire sample obtained by dividing the mass of the sample (for example, a cushion part, an absorber, etc.) by the area.
- the cushion portion is preferably about 0.1 to about 3.6 N, more preferably about 0.2 to about 3.0 N, and even more preferably about 0.3 to about 2. It has a compression force of 0N.
- the compressive force is less than about 0.1 N, the absorbent article is deformed in a convex shape, and then the compression from the wearer's leg is lost and the cushion part is repelled to quickly return the absorbent article to the original shape. It may not be possible.
- the said compression force exceeds about 3.6 N, there exists a tendency for the repulsive force of a cushion part to be too large, and for an absorbent article to become difficult to carry out convex deformation.
- FIG. 8 is a schematic view showing an example of an apparatus for measuring the compressive force.
- FIG. 8A is a diagram of the compressive force measuring device 21 as viewed from above
- FIG. 8B is a diagram of the compressive force measuring device 21 as viewed from the side.
- the compressive force measuring device 21 shown in FIG. 8 includes an operating table 23 that can reciprocate left and right on a stand 22 and a digital force gauge that is installed on the operating table 23 and measures compressive force. 24 and a sample stage 25 on which a sample to be measured is placed.
- the sample stage 25 has a sample 26 to be measured, two cylindrical compression parts 27 that are arranged so as to sandwich the sample 26, and a stopper for fixing one of the compression parts. 28 is arranged.
- Examples of the stand 22 include a digital force gauge stand manufactured by Nidec Sympo Corporation, such as FGS-50X-H.
- Examples of the digital force gauge 24 include a digital force gauge manufactured by Nidec-Simpo Corporation, for example, a FGP-0.5 worn with a push adapter (square, side length: 15 mm).
- Examples of the compression part 27 include an AS-one plastic petri dish (mass: 38.5 g, diameter: 100 mm, height: 30 mm).
- the sample 26, specifically, the cushion part taken out from the absorbent article is placed between the two compression parts 27.
- the cushion part is set such that the two compression parts 27 compress the center position in the longitudinal direction of the cushion part in the width direction of the cushion part.
- the longitudinal direction and width direction regarding a cushion part mean the longitudinal direction and width direction of the absorbent article which the said cushion part comprises.
- the digital force gauge 24 is arranged so that the adapter compresses around a position 6 mm from the bottom of the compression part 27.
- the digital force gauge 24 is moved 20 mm so as to push the sample 26 at a speed of 100 mm / min, the sample 26 is compressed, the maximum value at that time is read, and the value of the compression force is adopted.
- the density of the cushion portion constituting the middle-high portion is different between the outer peripheral portion and the central portion of the middle-high portion, and the density of the cushion portion in the outer peripheral portion is the cushion portion in the central portion.
- the absorbent article may be referred to as “absorbent article including a cushion portion having a density difference”).
- the shape of the labia of adult women is not constant and varies from person to person, but the labia of adult women is less likely to deform when the body is moved than the labia.
- the large labia differs greatly in the degree of deformation when the body is moved depending on the body shape of the woman. When the body is moved, the large labia is very easily deformed when the body is moved.
- the relatively low-density cushion part in the middle part of the middle and high parts has low rigidity, and when in contact with the small labia, it deforms along the shape of the small labia, Bury the labia minora.
- a relatively high-density cushion portion in the outer peripheral portion of the middle-high portion has high rigidity, and keeps contacting the boundary between the small labia and the large labia or the large labia when dry before absorbing menstrual blood.
- the relatively high-density cushion portion in the outer peripheral portion of the middle-high portion has a high compression recovery property, and therefore continues to contact the excretory opening having a complicated shape even when wet after absorbing menstrual blood.
- the “excretion opening contact area” means an area in contact with the wearer's excretion opening, and the above “excretion opening” mainly means the labia minora, but the outer peripheral part of the middle and high parts However, it does not prevent you from touching the labia.
- the middle part of the middle and high part is easily compressed, so that it deforms into a concave shape along the shape of the wearer's small labia while wearing, and the small labia is buried.
- the top sheet is brought into close contact with the vaginal opening to prevent menstrual blood from spreading excessively on the top sheet.
- the top sheet is in close contact with the vaginal opening, so that the distance between the vaginal opening and the absorber is close during wearing, and the cushion part is mainly heated.
- the menstrual blood passes through the top sheet and the cushion portion without being diffused in the plane direction, and is quickly transferred to the absorbent body. Once the passage of menstrual blood is made, the area is hydrophilized. Therefore, menstrual blood passes through the top sheet and the cushion portion and absorbs quickly after absorption of menstrual blood for the second and subsequent times. Transition.
- the absorbent article including the cushion part having the above density difference
- body pressure is applied, the volume of the cushion part is temporarily reduced, and a large amount of menstrual blood stays in the cushion part where the volume is reduced. Even so, when the body pressure becomes weak, the bulk of the cushion part is quickly recovered, centering on the outer peripheral part of the middle and high parts, so that menstrual blood is quickly transferred to the absorbent body.
- the absorbent article containing the cushion part which has the said density difference can be formed by squeezing a top sheet and an absorber at least in the outer edge vicinity of a cushion part, for example.
- a top sheet and an absorber at least in the outer edge vicinity of a cushion part, for example.
- the cushion part in the outer peripheral part of the middle and high parts can be made higher than the density of the cushion portion in the middle portion of the middle-high portion.
- the degree of compression of the cushion portion is low and the thickness thereof is not as thin as that of the outer peripheral portion.
- An absorbent article including a cushion part having the above density difference, more specifically, an absorbent article having a squeezed part formed by squeezing at least a top sheet and an absorber near the outer edge of the cushion part, for example, , (I) squeezing the top sheet and the absorbent body on the outside of the cushion part, and (ii) squeezing the top sheet, the cushion part and the absorbent body on the outer edge of the cushion part. It can be manufactured by forming a part.
- the absorbent article containing the cushion part which has the said density difference is, for example, squeezing the outer edge of a cushion part, and then a liquid-impermeable back sheet, an absorber, a cushion part, and a top sheet in order.
- the top sheet By having at least a compressed portion formed by pressing the top sheet and the absorbent body in the vicinity of the outer edge of the cushion section, the top sheet is difficult to peel from the absorbent body when wet after absorbing menstrual blood, for example. Moreover, the high density of the cushion part in the outer peripheral part of the middle-high part can be maintained.
- the vicinity of the outer edge” regarding the cushion part is a concept including not only the outer edge of the cushion part but also the inner side of the outer edge of the cushion part and the outer side of the outer edge of the cushion part.
- “near” is preferably a range of ⁇ 15%, more preferably ⁇ 10% of the distance from the center of the cushion portion to the outer edge of the cushion portion in the planar direction of the absorbent article, and more preferably ⁇ 10%. Means a range of ⁇ 5%.
- center regarding a cushion part means the center of the longitudinal direction and width direction of an absorbent article.
- FIGS. 1 to 5 there is a squeezed portion formed by continuously squeezing the top sheet and the absorbent body on the outside of the cushion portion, but the absorbency in another embodiment of the present disclosure
- a pressing part formed by intermittently pressing the top sheet and the absorbent body outside the cushion part.
- the absorbent article in still another embodiment of the present invention there is a pressing portion formed by continuously or intermittently pressing the top sheet, the cushion portion, and the absorbent body at the edge of the cushion portion, and the present invention.
- the shape of the cushion part before being incorporated into the absorbent article is not particularly limited.
- the projection in the thickness direction of the absorbent article has a shape similar to the labia, for example, a substantially circular shape, a substantially elliptical shape, It can be a substantially rounded rectangle, a figure surrounded by two arcs, or the like.
- the cushion portion may have a constant thickness in the thickness direction of the absorbent article, the thickness may increase from the center toward the outer edge, or the thickness may increase from the center toward the outer edge. Can be thinned.
- the cushion part when the thickness of the cushion part becomes thinner from the center toward the outer edge, when the absorber and the top sheet are squeezed, the density of the cushion part in the outer peripheral part of the middle and high parts is Since it may be difficult to increase the density of the cushion part, in the absorbent article including the cushion part having the above density difference, the cushion part has a constant thickness or the thickness from the center to the outer edge. What becomes thick toward it is preferable. Further, the basis weight of the cushion portion may vary depending on the location.
- FIG. 9 is a diagram showing an example of the shape of the cushion part before being incorporated into the absorbent article.
- the projection in the thickness direction of the absorbent article is substantially elliptical and has a constant thickness.
- the cushion part 6 shown by FIG.9 (b) is the shape which the projection view of the thickness direction of an absorbent article consists of two arcs, and thickness is constant.
- the projection in the thickness direction of the absorbent article is a substantially rounded rectangle, and the thickness is constant.
- the projection in the thickness direction of the absorbent article is substantially elliptical, and the thickness decreases from the center toward the outer edge.
- the density of the cushion portion at the middle portion of the mid-high portion is preferably about 0.001 to 0.1 g / cm 3 , more preferably about 0.005 to about 0.08 g / cm 3 , and still more preferably about 0.01. To about 0.05 g / cm 3 .
- the absorbent article may be convexly deformed when compression in the width direction is not applied to the absorbent article, and the repulsive force of the cushion portion is small. In some cases, it is difficult to return the convex-shaped absorbent article to its original shape, and compression recovery tends to be insufficient when wet after absorbing menstrual blood.
- the repulsive force of the cushion portion is excessively large, the absorbent article is not easily deformed in a convex shape, and the twist may occur when the wearer closes the leg. , And tends to deform along the wearer's small labia, making it difficult to fit the labia.
- the density of the cushion part in the center part and outer peripheral part of a middle-high part is measured as follows.
- a two-dimensional laser displacement meter measure the thickness t (cm) of the cushion portion at the position to be measured.
- Examples of the two-dimensional laser displacement meter include a high-precision two-dimensional laser displacement meter LJ-G series (model: LJ-G030) manufactured by Keyence Corporation.
- the thickness of the cushion part at the position to be measured is calculated by subtracting the thickness of the region where the cushion part does not exist from the thickness of the absorbent article at the position to be measured.
- the ratio of the density at different positions of the cushion portion can be simply compared by their thickness. That is, when the basis weight of the cushion portion is constant, it means that the thinner the cushion portion, the higher the density of the cushion portion.
- the density of the cushion part in the outer peripheral part of the middle-high part is higher than the density of the cushion part in the middle part of the middle-high part, preferably about 1.1 to about 5. 0 times higher, more preferably about 1.2 to about 4.0 times higher, and more preferably about 1.5 to about 3.0 times higher.
- the ratio is less than about 1.1 times, when wet, there is a tendency that the compression recovery property of the cushion portion at the outer peripheral portion of the middle and high portions is insufficient, and when the ratio is more than about 5.0 times
- the rigidity of the cushion part in the outer peripheral part of a middle-high part is high, and there exists a tendency for a wearer to remember a foreign material feeling easily.
- the cushion portion preferably has a longitudinal length of the absorbent article, preferably about 10 to about 100 mm, of about 30 to about 300 mm, more preferably about 40 to about 250 mm, and even more preferably about 50 to about 100 mm. More preferably from about 20 to about 70 mm, and even more preferably from about 25 to about 50 mm, in the width direction of the absorbent article.
- the middle and high parts fit into the excretion opening of the wearer, particularly the labia, and leakage can be suppressed. If the size of the cushion part is smaller than the above range, the middle and high part will not fit into the wearer's excretion opening, especially the labia, and leakage will easily occur, and if the size of the cushion part is larger than the above range, it will be worn Sometimes it is easy to feel a sense of incongruity, and a gap with the labia tends to occur, and leakage tends to occur.
- longitudinal direction means the longitudinal direction of the absorbent article
- width direction means the width direction of the absorbent article
- thickness direction means the thickness direction of the absorbent article
- the cushion part preferably has a maximum thickness of about 50% or more after absorbing 2 g of equine EDTA blood and before absorbing horse EDTA blood, and has a maximum thickness of about 60% or more. More preferably, and even more preferably a maximum thickness of about 70% or more.
- 2 g of equine EDTA blood is dripped is that the amount of menstrual blood excreted at one time by humans is generally 2 g.
- 2 g of equine EDTA blood is dripped on the entire cushion part using a pipette.
- the cushion part contains a water-repellent material, the equine EDTA blood is difficult to enter the cushion part. In such a case, equine EDTA blood may be absorbed by the cushion portion while pressurizing the cushion portion.
- the maximum thickness of the cushion part after absorbing 2 g of equine EDTA blood is measured after 1 minute has elapsed since all of the equine EDTA blood has been absorbed. Further, the maximum thickness of the cushion portion is measured using the above-described two-dimensional laser displacement meter. The EDTA blood will be described later.
- the absorbent article has a curved structure that curves with the middle and high portions facing inward.
- the absorbent article fits to the curve of the wearer's body, and absorbed menstrual blood is less likely to leak.
- the curved structure can be formed, for example, by passing an elastic member, for example, a rubber thread, a stretchable film, etc., on both sides in the longitudinal direction of the absorbent article, and applying tension to both sides in the longitudinal direction of the absorbent article. .
- the absorbent article has a flat structure that is not curved with the middle-high portion facing inward.
- the liquid-permeable top sheet has a plurality of ridges and a plurality of grooves extending in the longitudinal direction of the absorbent article on the skin contact surface (
- a top sheet having a plurality of ridges and a plurality of grooves extending in the longitudinal direction of the absorbent article may be simply referred to as a top sheet having a ridge groove structure).
- the top sheet can be produced according to the methods described in JP-A-2008-025078, JP-A-2008-025079 and the like.
- the top sheet is manufactured according to the method described in Japanese Patent Application Laid-Open Nos. 2011-222010, 2011-2226011, and the like, and has a ridge groove structure. It is.
- the top sheet having the ridge groove structure is a pair of gear rolls having a rotation axis perpendicular to the conveying direction, and a gap between the plurality of teeth arranged on the outer peripheral surfaces of the gear rolls while meshing with each other. Can be formed by fluid treatment through the topsheet to be treated.
- the draw ratio of the gear roll is preferably about 105% or more, more preferably about 105 to about 500%, further preferably about 120 to 300%, and further preferably about 130%. About 200%.
- the stretch ratio is less than about 105%, the stretchability of the top sheet is insufficient, the cushion part is easily crushed during the manufacture of absorbent articles, and when the stretch ratio is greater than about 500%, There is a tendency that the top sheet is easily torn during the manufacture of the property article.
- the said draw ratio is the following formula when the gear pitch is P and the gear biting depth is D: Means the value calculated by.
- the liquid-permeable top sheet has a plurality of slits.
- the slit can be widened and the cushion portion can be prevented from being excessively crushed during the manufacture of the absorbent article.
- the top sheet having the plurality of slits can be formed by passing the top sheet through a slit roll in which vertically long slits are arranged in a staggered manner.
- the top sheet having the plurality of slits can be manufactured, for example, as described in JP-T-2002-528174.
- the liquid-permeable top sheet has a plurality of pin openings.
- a top sheet having a ridge groove structure, slits, pin openings, etc. has an excessive cushion part due to a change in the shape of the groove structure of the top sheet, opening / closing of the slit and pin openings, etc. during manufacture of the absorbent article. Can be prevented from being crushed. From this point of view, it is preferable that the ridge groove structure, slit, pin opening portion, etc. of the top sheet are present at least in the portion in contact with the cushion portion, i.e., the portion constituting the middle-high portion. May be present.
- the absorbent article of the present disclosure can have any shape such as a rectangle, an ellipse, a saddle, and the like, and may have a so-called flap that prevents deviation from clothes, for example, shorts.
- the size of the absorbent article of the present disclosure is preferably A longitudinal length of about 100 to about 500 mm, more preferably about 120 to about 350 mm, and more preferably about 150 to about 250 mm, preferably about 40 to about 200 mm, more preferably about 45 to about 180 mm, and further Preferably, it has a length in the width direction of about 50 to 100 mm.
- the absorbent body preferably has a longitudinal length of about 80 to about 350 mm, more preferably about 100 to 300 mm, and more preferably about 120 to 250 mm.
- the absorbent body preferably has a longitudinal length of about 80 to about 350 mm, more preferably about 100 to 300 mm, and more preferably about 120 to 250 mm.
- the buttock is a part that changes greatly when the wearer walks, sits, etc., and when a twist occurs in the absorber in contact with the buttock, the absorbent in the excretory opening, particularly the part in contact with the labia
- the absorbent body preferably has a length in the width direction of about 30 to about 100 mm, more preferably about 35 to about 80 mm, and more preferably about 40 to about 70 mm. If the width of the absorbent body is excessively larger than the width of the wearer's crotch, the absorbent body is deformed, causing menstrual blood to spread to other areas and / or transferred, and the absorbed menstrual blood leaks. Because there are cases.
- the absorbent is preferably an average of about 100 to about 1,000 g / m 2 , more preferably about 150 to 700 g / m 2 , and even more preferably about 200 to about 500 g / m 2 .
- Has a basis weight When the average basis weight is less than about 100 g / m 2 , the absorbent article tends to be deformed regardless of the folding axis. When the average basis weight exceeds about 1,000 g / m 2 , the compressed portion and the folding axis may be difficult to be formed, and the absorbent article tends to be difficult to bend starting from the folding axis.
- the basis weight of the center region in the width direction of the absorbent body is less than the basis weight of the side edge region, and the basis weight of the center region in the width direction of the absorbent body is Compared to the basis weight of the edge region, preferably in the range of about 80% or less, more preferably about 1 to about 80%, more preferably about 10 to about 70%, and more preferably about 30 to about 50%. is there.
- the absorbent article is likely to be convexly deformed with the folding axis as a starting point.
- the “central region” in the width direction of the absorber means a region of 0 to 20% of the distance from the center in the width direction of the absorber to the end in the width direction of the absorber.
- the absorbent body when the absorbent body mainly includes pulverized pulp, the absorbent body in which the basis weight of the central region in the width direction is smaller than the basis weight of the side edge region in the width direction makes it difficult for the pulverized pulp to be laminated in the central region.
- the absorbent body includes a laminated sheet such as an airlaid pulp sheet, it can be produced by reducing the number of laminated layers in the central region.
- the mid-high section has an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C. or less, and about 0.00 to about 100 g of water at 25 ° C.
- IOB Inorganic Organic Balance
- IOB is an index indicating a balance between hydrophilicity and lipophilicity.
- Oda et al. IOB value calculated by inorganic value / organic value.
- the inorganic value and the organic value are represented by Fujita Minoru, “Prediction of organic compounds and conceptual diagram of organic compounds”, chemistry area Vol. 11, no. 10 (1957) p. 719-725).
- Table 1 summarizes the organic and inorganic values of the major groups by Mr. Fujita.
- the IOB is about 0.00 to about 0.60, preferably about 0.00 to about 0.50, and preferably about 0.00 to about 0.40. More preferred is about 0 to about 0.30. This is because the lower the IOB, the higher the organicity and the higher the affinity with blood cells.
- melting point means a peak top temperature of an endothermic peak when changing from a solid state to a liquid state when measured with a differential scanning calorimeter at a heating rate of 10 ° C./min.
- the melting point can be measured using, for example, a DSC-60 type DSC measuring apparatus manufactured by Shimadzu Corporation.
- the blood modifying agent may be liquid at room temperature or solid as long as it has a melting point of about 45 ° C. or lower, that is, whether the melting point is about 25 ° C. or higher, or less than about 25 ° C. Well, and can have a melting point of, for example, about ⁇ 5 ° C., about ⁇ 20 ° C., and the like. The reason why the melting point of the blood modifying agent is about 45 ° C. or less will be described later.
- the blood modifying agent has a lower melting point, but preferably has a low vapor pressure.
- the blood pressure of the blood modifying agent is preferably about 0 to about 200 Pa, more preferably about 0 to about 100 Pa, and about 0 to about 10 Pa at 25 ° C. (1 atm). More preferably, it is more preferably from about 0 to about 1 Pa, and even more preferably from about 0.0 to about 0.1 Pa.
- the vapor pressure is preferably about 0 to about 700 Pa at 40 ° C. (1 atm), and is about 0 to about 100 Pa.
- the melting point of the blood modifying agent can be properly used according to the climate, the length of wearing time, and the like. For example, in an area where the average temperature is about 10 ° C. or less, even when the menstrual blood is excreted and then cooled by the ambient temperature by adopting a blood modifying agent having a melting point of about 10 ° C. or less.
- the blood modifying agent stably reforms the blood.
- the melting point of the blood modifying agent is preferably higher in the range of 45 ° C. or lower. This is because the blood modifying agent is difficult to move even when it is worn for a long time, and is hardly affected by sweat, friction at the time of wearing, and the like.
- the water solubility of 0.00-0.05 g was obtained by adding 0.05 g of sample to 100 g of deionized water at 25 ° C., leaving it to stand for 24 hours, and after 24 hours, gently stirring as necessary. Next, it is measured by visually evaluating whether or not the sample is dissolved.
- dissolution includes a case where the sample is completely dissolved in deionized water to form a uniform mixture and a case where the sample is completely emulsified.
- “Complete” means that there is no lump of sample in deionized water.
- top sheet is coated with a surfactant for the purpose of changing blood surface tension and the like to absorb blood rapidly.
- surfactants generally have high water solubility
- top sheets coated with surfactants are well-suited to hydrophilic components (blood plasma, etc.) in blood, but rather leave blood on the top sheet.
- the blood modifying agent has low water solubility, unlike the conventionally known surfactants, blood is not allowed to remain on the top sheet, but is quickly transferred to the absorber.
- solubility in 100 g of water at 25 ° C. may be simply referred to as “water solubility”.
- a weight average molecular weight means the value of polystyrene conversion calculated
- GPC measurement conditions include the following. Model: Hitachi High-Technologies Corporation High-Performance Liquid Chromatogram Lachrom Elite Column: SHODEX KF-801, KF-803 and KF-804 manufactured by Showa Denko K.K. Eluent: THF Flow rate: 1.0 mL / min Driving amount: 100 ⁇ L Detection: RI (differential refractometer)
- the weight average molecular weight described in the Example of this specification is measured on the said conditions.
- the blood modifying agent is preferably the following (i) to (iii), (I) hydrocarbons, (Ii) from (ii-1) a hydrocarbon moiety and (ii-2) a carbonyl group (—CO—) and an oxy group (—O—) inserted between the CC single bonds of the hydrocarbon moiety.
- the hydrocarbon moiety A compound having one or a plurality of the same or different groups selected from the group consisting of a carboxyl group (—COOH) and a hydroxyl group (—OH), which replaces a hydrogen atom; As well as any combination thereof.
- hydrocarbon means a compound composed of carbon and hydrogen, and a chain hydrocarbon, for example, a paraffinic hydrocarbon (also referred to as an alkane, which does not include a double bond and a triple bond).
- a paraffinic hydrocarbon also referred to as an alkane, which does not include a double bond and a triple bond.
- Olefinic hydrocarbons including one double bond, also referred to as alkene
- acetylenic hydrocarbons including one triple bond, also referred to as alkyne
- hydrocarbons containing two or more bonds selected from the above and cyclic hydrocarbons such as aromatic hydrocarbons and alicyclic hydrocarbons.
- the hydrocarbon is preferably a chain hydrocarbon and an alicyclic hydrocarbon, more preferably a chain hydrocarbon, a paraffinic hydrocarbon, an olefinic hydrocarbon, and two double bonds. More preferred are hydrocarbons (not including triple bonds), and more preferred are paraffinic hydrocarbons.
- the chain hydrocarbon includes a straight chain hydrocarbon and a branched chain hydrocarbon.
- each oxy group (—O—) is not adjacent. Therefore, the compounds (ii) and (iii) do not include compounds having a continuous oxy group (so-called peroxides).
- At least one hydrogen atom in the hydrocarbon moiety is more than a hydroxyl group (-) than in a compound in which at least one hydrogen atom in the hydrocarbon moiety is substituted with a carboxyl group (-COOH).
- Compounds substituted with OH) are preferred.
- Table 1 since the carboxyl group binds to menstrual metals and the like, and the inorganic value increases significantly from 150 to 400 or more, the blood modifying agent having a carboxyl group is used at the time of use. This is because the value of IOB exceeds about 0.60, and the affinity with blood cells may be reduced.
- the blood modifying agent is more preferably the following (i ′) to (iii ′), (I ′) hydrocarbon, (Ii ′) (ii′-1) a hydrocarbon moiety and (ii′-2) a carbonyl bond (—CO—), an ester bond (—COO) inserted between the C—C single bonds of the hydrocarbon moiety.
- the blood modifying agent preferably has about 1.8 or less carbonyl bonds (—CO—) and 2 or less ester bonds (—COO—) per 10 carbon atoms in the hydrocarbon moiety.
- About 1.5 or less carbonate bonds (—OCOO—), about 6 or less ether bonds (—O—), about 0.8 or less carboxyl groups (—COOH), and / or hydroxyl groups (—OH) ) Can be a compound having about 1.2 or less.
- the blood modifying agent is more preferably the following (A) to (F), (A) (A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the chain An ester with a compound having one carboxyl group for substituting a hydrogen atom in the hydrocarbon moiety, (B) (B1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the chain An ether with a compound having one hydroxyl group replacing a hydrogen atom of the hydrocarbon moiety, (C) (C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing a chain hydrocarbon moiety and 2 to 4 carboxyl groups replacing a hydrogen atom in the chain hydrocarbon moiety; C2) an ester of a compound having a chain hydrocarbon mo
- (A1) A compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety (hereinafter sometimes referred to as “compound (A1)”)
- a chain hydrocarbon tetraol such as an alkanetetraol, such as pentaerythritol
- a chain hydrocarbon triol such as an alkanetriol, such as glycerine
- a chain hydrocarbon diol such as an alkanediol, such as, for example, Glycol.
- Examples of the compound (A2) having a chain hydrocarbon moiety and one carboxyl group that replaces the hydrogen atom of the chain hydrocarbon moiety include: , Compounds in which one hydrogen atom on a hydrocarbon is substituted with one carboxyl group (—COOH), for example, fatty acids.
- Examples of the compound (A) include (a 1 ) an ester of a chain hydrocarbon tetraol and at least one fatty acid, (a 2 ) an ester of a chain hydrocarbon triol and at least one fatty acid, and (a 3 ) Esters of chain hydrocarbon diols with at least one fatty acid.
- ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid examples include the following formula (1): Tetraesters of pentaerythritol and fatty acids of the following formula (2): Triesters of pentaerythritol and fatty acids of the following formula (3): Diester of pentaerythritol and fatty acid of the following formula (4): And monoesters of pentaerythritol and fatty acids. (Wherein R 1 to R 4 are each a chain hydrocarbon)
- the ester of pentaerythritol and fatty acid has the above-mentioned IOB, melting point and water solubility.
- a saturated fatty acid for example, a C 2 to C 30 saturated fatty acid, for example, acetic acid (C 2 ) (C 2 represents the number of carbon atoms, R 1 C, R 2 C, R 3 C or R 4 C, the same applies hereinafter), propanoic acid (C 3 ), butanoic acid (C 4 ) and isomers thereof such as 2-methylpropanoic acid (C 4 ), Pentanoic acid (C 5 ) and isomers thereof such as 2-methylbutanoic acid (C 5 ), 2,2-dimethylpropanoic acid (C 5 ), hexanoic acid (C 6 ), heptanoic acid (C 7 ), octanoic acid (C 8) Beauty isomers thereof, e.g., 2-ethylhexanoic acid (C 8), nonanoic acid (C 9), decanoic acid (C 10), dode
- the fatty acid can also be an unsaturated fatty acid.
- unsaturated fatty acid include C 3 to C 20 unsaturated fatty acids such as monounsaturated fatty acids such as crotonic acid (C 4 ), myristoleic acid (C 14 ), palmitoleic acid (C 16 ), Oleic acid (C 18 ), elaidic acid (C 18 ), vaccenic acid (C 18 ), gadoleic acid (C 20 ), eicosenoic acid (C 20 ), etc., diunsaturated fatty acids such as linoleic acid (C 18 ), Triunsaturated fatty acids such as eicosadienoic acid (C 20 ), such as linolenic acid, such as ⁇ -linolenic acid (C 18 ) and ⁇ -linolenic acid (C 18 ), pinolenic acid (C 18 ), eleostearic acid, For example, ⁇ -eleostearic acid (C
- the ester of pentaerythritol and fatty acid is an ester of pentaerythritol and a fatty acid derived from a saturated fatty acid, that is, an ester of pentaerythritol and a saturated fatty acid, considering the possibility of modification by oxidation or the like. preferable.
- the ester of pentaerythritol and fatty acid is preferably a diester, triester or tetraester, more preferably a triester or tetraester, in order to reduce IOB and make it more hydrophobic. And tetraesters are more preferred.
- the total number of carbon atoms of the fatty acid constituting the tetraester of pentaerythritol and fatty acid that is, in the above formula (1), R 1 C, R 2 C, R 3 C and When the total number of carbon atoms in the R 4 C portion is 15, IOB is 0.60. Therefore, in the tetraester of pentaerythritol and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbons is about 15 or more.
- tetraester of pentaerythritol and fatty acid for example, pentaerythritol, hexanoic acid (C 6 ), heptanoic acid (C 7 ), octanoic acid (C 8 ), for example, 2-ethylhexanoic acid (C 8 ), And tetraesters with nonanoic acid (C 9 ), decanoic acid (C 10 ) and / or dodecanoic acid (C 12 ).
- the total number of carbon atoms of the fatty acid constituting the triester of pentaerythritol and fatty acid that is, in the above formula (2), R 1 C, R 2 C and R 3 C moieties
- the IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbon atoms of the fatty acid is about 19 or more.
- the total number of carbon atoms of the fatty acid constituting the diester of pentaerythritol and fatty acid that is, the total number of carbon atoms of the R 1 C and R 2 C moieties in the above formula (3) is In the case of 22, the IOB is 0.59. Therefore, in the diester of pentaerythritol and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbon atoms of the fatty acid is about 22 or more.
- the number of carbons of the fatty acid constituting the monoester of pentaerythritol and fatty acid that is, in the above formula (4), the IOB is 25 when the carbon number of the R 1 C portion is 25. 0.60. Therefore, in the monoester of pentaerythritol and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the number of carbon atoms of the fatty acid is about 25 or more. In the above calculation, the influence of double bond, triple bond, iso branch, and tert branch is not taken into consideration.
- esters of pentaerythritol and fatty acids examples include Unistar H-408BRS, H-2408BRS-22 (mixed product) and the like (manufactured by NOF Corporation).
- ester of (a 2 ) chain hydrocarbon triol and at least one fatty acid examples include the following formula (5): Triester of glycerin and fatty acid of the following formula (6): Diesters of glycerin and fatty acids and the following formula (7): (Wherein R 5 to R 7 are each a chain hydrocarbon) Monoester of glycerin and fatty acid.
- the ester of the glycerin and the fatty acid constituting the ester of the glycerin and the fatty acid, as long as the ester of the glycerin and the fatty acid satisfies the requirements for the IOB, melting point and water solubility,
- the fatty acids listed in “Ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid”, that is, saturated fatty acids and unsaturated fatty acids, and the like are modified by oxidation or the like.
- it is preferable to use an ester of glycerin and a fatty acid derived from a saturated fatty acid that is, an ester of glycerin and a saturated fatty acid.
- ester of glycerin and fatty acid is preferably a diester or triester, and more preferably a triester, in order to reduce IOB and make it more hydrophobic.
- the triester of glycerin and a fatty acid is also referred to as a triglyceride.
- triester of glycerin and octanoic acid C 8
- triester of glycerin and decanoic acid C 10
- glycerin and dodecanoic acid C 12
- triesters of glycerin and 2 or 3 fatty acids and mixtures thereof.
- Examples of the triesters of glycerin and two or more fatty acids include triesters of glycerin and octanoic acid (C 8 ) and decanoic acid (C 10 ), glycerin, octanoic acid (C 8 ), and decane.
- Examples thereof include triesters with (C 16 ) and octadecanoic acid (C 18 ).
- the total number of carbon atoms of the fatty acid constituting the triester of glycerin and fatty acid that is, R 5 C in formula (5) in order to make the melting point about 45 ° C. or less.
- R 6 C and R 7 C moieties preferably have a total carbon number of about 40 or less.
- the total number of carbon atoms of the fatty acid constituting the triester of glycerin and fatty acid that is, in the formula (5), R 5 C, R 6 C and R 7 C moieties.
- the IOB is 0.60. Therefore, in the triester of glycerin and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbon atoms of the fatty acid is about 12 or more.
- the triester of glycerin and a fatty acid is a so-called fat and is a component that can constitute a human body, and thus is preferable from the viewpoint of safety.
- triesters of glycerin and fatty acids include tricoconut oil fatty acid glyceride, NA36, panacet 800, panacet 800B and panacet 810S, and tri-C2L oil fatty acid glyceride and tri-CL oil fatty acid glyceride (above, manufactured by NOF Corporation). ) And the like.
- the diester of glycerin and fatty acid is also called diglyceride.
- diester of glycerin and decanoic acid (C 10 ) diester of glycerin and dodecanoic acid (C 12 ), glycerin and hexadecanoic acid (C 16 ) Examples include diesters, diesters of glycerin and two fatty acids, and mixtures thereof.
- the total number of carbon atoms of the fatty acid constituting the diester of glycerin and fatty acid that is, the total number of carbon atoms of the R 5 C and R 6 C moieties in the formula (6) is 16.
- the IOB is 0.58. Accordingly, in the diester of glycerin and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbon atoms of the fatty acid is about 16 or more.
- the monoester of the glycerin and the fatty acid is also referred to as a monoglyceride, and examples thereof include glycerin icosanoic acid (C 20 ) monoester, glycerin docosanoic acid (C 22 ) monoester, and the like.
- the monoester of glycerin and fatty acid the number of carbon atoms of the fatty acid constituting the monoester of glycerin and fatty acid, that is, when the carbon number of the R 5 C moiety in the formula (7) is 19, the IOB is 0.59. It becomes. Therefore, in the monoester of glycerin and fatty acid, when the carbon number of the fatty acid is about 19 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.
- ester of (a 3 ) chain hydrocarbon diol and at least one fatty acid examples include C 2 to C 6 chain hydrocarbon diols such as C 2 to C 6 glycols such as ethylene glycol, propylene glycol, butylene. Examples thereof include monoesters or diesters of glycol, pentylene glycol or hexylene glycol and a fatty acid.
- ester of the chain hydrocarbon diol and at least one fatty acid for example, the following formula (8): R 8 COOC k H 2k OCOR 9 (8) (Wherein k is an integer from 2 to 6 and R 8 and R 9 are each a chain hydrocarbon) A diester of a C 2 -C 6 glycol with a fatty acid and the following formula (9): R 8 COOC k H 2k OH (9) (Wherein k is an integer from 2 to 6 and R 8 is a chain hydrocarbon) And monoesters of C 2 -C 6 glycols and fatty acids.
- the fatty acid to be esterified (corresponding to R 8 COOH and R 9 COOH in formula (8) and formula (9)) is C 2 -C 6 glycol.
- an ester of a fatty acid satisfying the above requirements of IOB, melting point and water solubility for example, “(a 1 ) ester of chain hydrocarbon tetraol and at least one fatty acid”
- the fatty acids listed in the above that is, saturated fatty acids and unsaturated fatty acids are mentioned, and saturated fatty acids are preferred in consideration of the possibility of modification by oxidation or the like.
- the ester of a C 2 ⁇ C 6 glycols and fatty acid in view of the potential for degradation by oxidation and the like, derived from saturated fatty acids, esters of C 2 ⁇ C 6 glycols and fatty acid, Nachi Suwa, C 2 An ester of ⁇ C 6 glycol and saturated fatty acid is preferred.
- the ester of C 2 -C 6 glycol and fatty acid is an ester of glycol and fatty acid derived from glycol having a large carbon number, for example, butylene glycol, in order to reduce IOB and make it more hydrophobic.
- An ester of glycol and fatty acid derived from pentylene glycol or hexylene glycol is preferable.
- ester of C 2 -C 6 glycol and fatty acid is preferably a diester in order to reduce IOB and make it more hydrophobic.
- examples of commercial products of the ester of C 2 -C 6 glycol and fatty acid include Compol BL and Compol BS (manufactured by NOF Corporation).
- Compound (B1) Compounds having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety are listed as “Compound (A)” as Compound (A1). For example, pentaerythritol, glycerin, and glycol.
- Examples of the compound (B2) having a chain hydrocarbon moiety and one hydroxyl group replacing the hydrogen atom of the chain hydrocarbon moiety include: , Compounds in which one hydrogen atom of a hydrocarbon is replaced by one hydroxyl group (—OH), for example, aliphatic monohydric alcohols, for example, saturated aliphatic monohydric alcohols and unsaturated aliphatic monohydric alcohols Is mentioned.
- saturated aliphatic monohydric alcohol examples include C 1 to C 20 saturated aliphatic monohydric alcohols such as methyl alcohol (C 1 ) (C 1 represents the number of carbon atoms, the same shall apply hereinafter), ethyl alcohol ( C 2 ), propyl alcohol (C 3 ) and isomers thereof such as isopropyl alcohol (C 3 ), butyl alcohol (C 4 ) and isomers thereof such as sec-butyl alcohol (C 4 ) and tert-butyl alcohol (C 4 ), pentyl alcohol (C 5 ), hexyl alcohol (C 6 ), heptyl alcohol (C 7 ), octyl alcohol (C 8 ) and isomers thereof such as 2-ethylhexyl alcohol (C 8 ), nonyl alcohol (C 9), decyl alcohol (C 10), dodecyl alcohol (C 12), tetradecyl alcohol (C 14), Hexadecyl alcohol (C 16), to
- Examples of the unsaturated aliphatic monohydric alcohol include those obtained by substituting one of the C—C single bonds of the saturated aliphatic monohydric alcohol with a C ⁇ C double bond, such as oleyl alcohol. It is commercially available from Shin Nippon Rika Co., Ltd. under the names of the Jamaica Coal series and the Angelo All series.
- Examples of the compound (B) include (b 1 ) ethers of chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol, such as monoether, diether, triether and tetraether, preferably diether, triether.
- Ethers and tetraethers more preferably triethers and tetraethers, and even more preferably tetraethers, ethers of (b 2 ) chain hydrocarbon triols and at least one aliphatic monohydric alcohol, such as monoethers, diethers and Triethers, preferably diethers and triethers, and more preferably triethers, and (b 3 ) ethers of chain hydrocarbon diols with at least one aliphatic monohydric alcohol, such as monoethers and diethers, and preferably Diether It is below.
- Examples of the ether of the chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol include, for example, the following formulas (10) to (13): (In the formula, R 10 to R 13 are each a chain hydrocarbon.) And tetraethers, triethers, diethers and monoethers of pentaerythritol and aliphatic monohydric alcohols.
- Examples of the ether of the chain hydrocarbon triol and at least one aliphatic monohydric alcohol include, for example, the following formulas (14) to (16): (Wherein R 14 to R 16 are each a chain hydrocarbon.) And triether, diether and monoether of glycerin and aliphatic monohydric alcohol.
- Examples of the ether of the chain hydrocarbon diol and at least one aliphatic monohydric alcohol include the following formula (17): R 17 OC n H 2n OR 18 (17) (Wherein n is an integer from 2 to 6 and R 17 and R 18 are each a chain hydrocarbon) A diether of a C 2 -C 6 glycol and an aliphatic monohydric alcohol, and the following formula (18): R 17 OC n H 2n OH (18) (Wherein n is an integer from 2 to 6 and R 17 is a chain hydrocarbon) And monoethers of C 2 -C 6 glycols and aliphatic monohydric alcohols.
- the total number of carbon atoms of the aliphatic monohydric alcohol constituting the tetraether of pentaerythritol and aliphatic monohydric alcohol that is, in the above formula (10)
- the IOB is 0.44. Therefore, in the tetraether of pentaerythritol and aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 4 or more, the IOB is about 0.00 to about 0.60. Fulfill.
- the triether of pentaerythritol and aliphatic monohydric alcohol the total number of carbon atoms of the aliphatic monohydric alcohol constituting the triether of pentaerythritol and aliphatic monohydric alcohol, that is, in the above formula (11),
- IOB is 0.57. Therefore, the triether of pentaerythritol and aliphatic monohydric alcohol satisfies the requirement that the IOB is about 0.00 to about 0.60 when the total number of carbon atoms of the aliphatic monohydric alcohol is about 9 or more. Fulfill.
- the total number of carbon atoms of the aliphatic monohydric alcohol constituting the diether of pentaerythritol and aliphatic monohydric alcohol that is, in the formula (12), R 10
- the IOB is 0.60. Therefore, in the diether of pentaerythritol and aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 15 or more, the IOB satisfies the requirement of about 0.00 to about 0.60. .
- the carbon number of the aliphatic monohydric alcohol constituting the monoether of pentaerythritol and aliphatic monohydric alcohol that is, in the above formula (13), R 10
- the IOB is 0.59. Therefore, in the monoether of pentaerythritol and aliphatic monohydric alcohol, the IOB satisfies the requirement of about 0.00 to about 0.60 when the aliphatic monohydric alcohol has about 22 or more carbon atoms.
- the total number of carbon atoms of the aliphatic monohydric alcohol constituting the triether of glycerin and aliphatic monohydric alcohol that is, in the formula (14), R
- the IOB is 0.50. Therefore, in the above triether of glycerin and aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 3 or more, IOB satisfies the requirement of about 0.00 to about 0.60. .
- the total number of carbon atoms of the aliphatic monohydric alcohol constituting the diether of glycerin and aliphatic monohydric alcohol that is, in the formula (15), R 14 and R 15
- the IOB is 0.58. Therefore, in the diether of glycerin and aliphatic monohydric alcohol, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbon atoms of the aliphatic monohydric alcohol is about 9 or more.
- the carbon number of the aliphatic monohydric alcohol constituting the monoether of glycerin and aliphatic monohydric alcohol that is, the carbon of R 14 moiety in the formula (16).
- the IOB is 0.58. Therefore, in the monoether of glycerin and aliphatic monohydric alcohol, the IOB satisfies the requirement of about 0.00 to about 0.60 when the aliphatic monohydric alcohol has about 16 or more carbon atoms.
- the IOB is about 0. Satisfy requirements of 00 to about 0.60.
- Compound (B) can be produced by dehydrating condensation of compound (B1) and compound (B2) in the presence of an acid catalyst.
- C1 Carboxylic acids, hydroxy acids, alkoxy acids or oxo acids (hereinafter referred to as “compounds”) containing a chain hydrocarbon moiety and 2 to 4 carboxyl groups that replace the hydrogen atoms of the chain hydrocarbon moiety.
- C1) may be referred to as, for example, a chain hydrocarbon carboxylic acid having 2 to 4 carboxyl groups, such as a chain hydrocarbon dicarboxylic acid such as an alkanedicarboxylic acid such as ethanedioic acid.
- Examples include rubonic acids such as alkanetetracarboxylic acids such as butanetetraacid, pentanetetraacid, hexanetetraacid, heptanetetraacid, octanetetraacid, nonanetetraacid and decanetetra
- the compound (C1) includes a chain hydrocarbon hydroxy acid having 2 to 4 carboxyl groups, for example, a chain chain having 2 to 4 carboxyl groups such as malic acid, tartaric acid, citric acid, isocitric acid and the like. Hydrocarbon alkoxy acids such as O-acetylcitric acid and chain hydrocarbon oxoacids having 2 to 4 carboxyl groups are included.
- C2 Examples of the compound having a chain hydrocarbon moiety and one hydroxyl group substituting a hydrogen atom of the chain hydrocarbon moiety include those listed in the section of “Compound (B)”, for example, An aliphatic monohydric alcohol is mentioned.
- compound (D) a compound having any one bond selected from the group consisting of a carbonate bond (—OCOO—)
- compound (D) a compound having any one bond selected from the group consisting of a carbonate bond (—OCOO—)
- compound (D) aliphatic
- examples include ethers of monohydric alcohols and aliphatic monohydric alcohols, (d 2 ) dialkyl ketones, esters of (d 3 ) fatty acids and aliphatic monohydric alcohols, and (d 4 ) dialkyl carbonates.
- the ether As the aliphatic monohydric alcohol constituting the ether (corresponding to R 19 OH and R 20 OH in the formula (19)), the ether satisfies the requirements for the IOB, melting point and water solubility.
- the aliphatic monohydric alcohol listed in the section of “Compound (B)” is not particularly limited.
- the total number of carbon atoms of the aliphatic monohydric alcohol constituting the ether that is, the number of carbon atoms of R 19 and R 20 in the above formula (19). Since the IOB is 0.50 when the sum of the two is 2, the IOB requirement is satisfied if the total number of carbon atoms is about 2 or more. However, when the total number of carbon atoms is about 6, the water solubility is as high as about 2 g, which is problematic from the viewpoint of vapor pressure. In order to satisfy the requirement of water solubility of about 0.00 to about 0.05 g, the total number of carbon atoms is preferably about 8 or more.
- dialkylketone As the dialkyl ketone, the following formula (20): R 21 COR 22 (20) (Wherein R 21 and R 22 are each an alkyl group) The compound which has is mentioned.
- the IOB requirement is satisfied if the total number of carbon atoms is about 5 or more.
- the water solubility is as high as about 2 g. Therefore, in order to satisfy the requirement of water solubility of about 0.00 to about 0.05 g, the total number of carbon atoms is preferably about 8 or more.
- the carbon number is preferably about 10 or more, and more preferably about 12 or more.
- the melting point is about ⁇ 50 ° C.
- the vapor pressure is about 230 Pa at 20 ° C.
- the dialkyl ketone can be obtained by a known method, for example, by oxidizing a secondary alcohol with chromic acid or the like.
- ester of the fatty acid and the aliphatic monohydric alcohol include the following formula (21): R 23 COOR 24 (21) (Wherein R 23 and R 24 are each a chain hydrocarbon) The compound which has is mentioned.
- Examples of the fatty acid constituting the ester are listed in “(a 1 ) ester of chain hydrocarbon tetraol and at least one fatty acid”.
- Fatty acids that is, saturated fatty acids or unsaturated fatty acids can be mentioned, and saturated fatty acids are preferable in consideration of the possibility of modification by oxidation or the like.
- Examples of the aliphatic monohydric alcohol constituting the ester include the aliphatic monohydric alcohols listed in the section “Compound (B)”.
- the total number of carbon atoms of the fatty acid and the aliphatic monohydric alcohol is 5
- the above IOB requirement is satisfied when the total number of carbon atoms in the R 23 C and R 24 portions is about 5 or more.
- the total number of carbon atoms is preferably about 12 or more. If the total number of carbon atoms is about 11 or more, the water solubility can satisfy the requirement of about 0.00 to about 0.05 g.
- ester of the fatty acid and the aliphatic monohydric alcohol examples include, for example, an ester of dodecanoic acid (C 12 ) and dodecyl alcohol (C 12 ), tetradecanoic acid (C 14 ), and dodecyl alcohol (C 12 ).
- ester of the above fatty acids and aliphatic monohydric alcohols examples include Electol WE20 and Electol WE40 (manufactured by NOF Corporation).
- the dialkyl carbonate since the IOB is 0.57 when the total number of carbon atoms of R 25 and R 26 is 6, if the total number of carbon atoms of R 25 and R 26 is about 6 or more, Satisfy requirements. In consideration of water solubility, the total number of carbon atoms of R 25 and R 26 is preferably about 7 or more, and more preferably about 9 or more.
- the dialkyl carbonate can be synthesized by a reaction between phosgene and an alcohol, a reaction between a chlorinated formate and an alcohol or an alcoholate, and a reaction between silver carbonate and an alkyl iodide.
- Examples of the polyoxy C 2 -C 6 alkylene glycol, or an ester or ether thereof include (e 1 ) polyoxy C 2 -C 6 alkylene glycol, (e 2 ) polyoxy C An ester of 2 to C 6 alkylene glycol and at least one fatty acid, (e 3 ) an ether of polyoxy C 2 to C 6 alkylene glycol and at least one aliphatic monohydric alcohol, (e 4 ) polyoxy C 2 to C 6 Esters of alkylene glycol with chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid, or chain hydrocarbon dicarboxylic acid, and (e 5 ) polyoxy C 2 -C 6 alkylene glycol and chain hydrocarbon tetra Examples include ethers with all, chain hydrocarbon triols, or chain hydrocarbon diols.
- the oxy C 2 -C 6 alkylene skeleton is preferably an oxypropylene skeleton, an oxybutylene skeleton, an oxypentylene skeleton, or an oxyhexylene skeleton from the viewpoint of lowering the IOB of the polyoxy C 2 -C 6 alkylene glycol. More preferred is an oxybutylene skeleton, an oxypentylene skeleton or an oxyhexylene skeleton.
- the polyoxy C 2 -C 6 alkylene glycol is represented by the following formula (23): HO- (C m H 2m O) n -H (23) (Where m is an integer from 2 to 6) Can be represented by:
- the homopolymer of formula (23) may include a homopolymer of propylene glycol, butylene glycol, pentylene glycol or hexylene glycol. From the above, in formula (23), m is about 3 to about 6, more preferably about 4 to about 6, and n is 2 or more.
- the value of n is such that the polyoxy C 2 -C 6 alkylene glycol has an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C. or less, and 100 g of water at 25 ° C. A value having a water solubility of about 0.00 to about 0.05 g.
- the weight average molecular weight of the polyoxy C 4 -C 6 alkylene glycol is preferably about 200 to about 10,000, more preferably about 250 to about 8,000, and even more preferably, It is in the range of about 250 to about 5,000.
- the weight average molecular weight of polyoxy C 3 alkylene glycol, ie, polypropylene glycol is preferably about 1,000 to about 10,000, more preferably about 3,000 to about 8 , And more preferably in the range of about 4,000 to about 5,000. This is because, when the weight average molecular weight is less than about 1,000, the water solubility does not satisfy the requirement, and the higher the weight average molecular weight, the more the absorber transfer speed and the whiteness of the top sheet tend to improve.
- ester of polyoxy C 2 -C 6 alkylene glycol and at least one fatty acid examples include the OH terminal of the polyoxy C 2 -C 6 alkylene glycol described in the section “(e 1 ) polyoxy C 2 -C 6 alkylene glycol”. In which one or both of them are esterified with a fatty acid, that is, monoesters and diesters.
- Examples of the fatty acid to be esterified in the ester of polyoxy C 2 -C 6 alkylene glycol and at least one fatty acid are listed in “Ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid”.
- Fatty acid that is, saturated fatty acid or unsaturated fatty acid, and saturated fatty acid is preferable in consideration of possibility of modification by oxidation or the like.
- Examples of commercially available esters of the above polyoxy C 2 -C 6 alkylene glycol and fatty acid include Wilbright cp9 (manufactured by NOF Corporation).
- Examples of the aliphatic monohydric alcohol to be etherified in the ether of polyoxy C 2 -C 6 alkylene glycol and at least one aliphatic monohydric alcohol include, for example, the aliphatic enumerated in the section of “Compound (B)”. A monohydric alcohol is mentioned.
- Esters of the above polyoxy C 2 -C 6 alkylene glycol and chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid, or chain hydrocarbon dicarboxylic acid are commercially available, and chain hydrocarbon tetracarboxylic acid. It can be produced by polycondensing an oxy C 2 -C 6 alkylene glycol to an acid, a chain hydrocarbon tricarboxylic acid, or a chain hydrocarbon dicarboxylic acid under known conditions.
- chain hydrocarbon tetraol, chain hydrocarbon triol, and chain hydrocarbon diol to be etherified include those described in the section of “Compound (A)”, such as pentaerythritol, glycerin, and glycol. Is mentioned.
- Examples of commercially available ethers of the above polyoxy C 2 -C 6 alkylene glycol and chain hydrocarbon tetraol, chain hydrocarbon triol, or chain hydrocarbon diol include, for example, Unilube (trademark) 5TP-300KB, and And Uniol (trademark) TG-3000 and TG-4000 (manufactured by NOF Corporation).
- Unilube (trademark) 5TP-300KB is a compound obtained by polycondensation of 65 mol of propylene glycol and 5 mol of ethylene glycol to 1 mol of pentaerythritol, its IOB is 0.39, and its melting point is less than 45 ° C. Yes, and the water solubility was less than 0.05 g.
- Uniol TM TG-3000 is a compound obtained by polycondensation of 50 mol of propylene glycol with 1 mol of glycerin, its IOB is 0.42, its melting point is less than 45 ° C., and its water solubility is 0.05 g. And the weight average molecular weight was about 3,000.
- Uniol TM TG-4000 is a compound obtained by polycondensation of 70 mol of propylene glycol with 1 mol of glycerin, its IOB is 0.40, its melting point is less than 45 ° C., and its water solubility is 0.05 g. And the weight average molecular weight was about 4,000.
- the ether of the polyoxy C 2 -C 6 alkylene glycol and the chain hydrocarbon tetraol, the chain hydrocarbon triol, or the chain hydrocarbon diol is also a chain hydrocarbon tetraol, a chain hydrocarbon triol, or It can be produced by adding C 2 -C 6 alkylene oxide to a chain hydrocarbon diol under known conditions.
- the chain hydrocarbon Since the chain hydrocarbon has an inorganic value of 0, the IOB is 0.00 and the water solubility is approximately 0 g. Therefore, if the melting point is about 45 ° C. or less, the blood It can be included in the modifier.
- the chain hydrocarbon include (f 1 ) chain alkanes such as straight chain alkanes and branched chain alkanes. For example, in the case of straight chain alkanes, the melting point is about 45 ° C. or less. In general, those having 22 or less carbon atoms are included. Moreover, when the vapor pressure is taken into consideration, those having 13 or more carbon atoms are generally included.
- the melting point may be lower at the same number of carbons than that of a straight chain alkane. Therefore, those having 22 or more carbon atoms may be included.
- a commercial item of the above-mentioned hydrocarbon for example, Pearl Ream 6 (NOF Corporation) can be mentioned.
- the above-mentioned blood modifying agent is considered in detail together with the examples, but it has been found that it has at least an action of lowering blood viscosity and surface tension.
- menstrual blood to be absorbed by the absorbent article contains proteins such as the endometrial wall. Cheap. Therefore, menstrual blood to be absorbed by the absorbent article tends to have a high viscosity, and when the top sheet is a nonwoven fabric or a woven fabric, the menstrual blood tends to clog between the fibers, and the wearer feels sticky. Almost, and menstrual blood diffuses on the surface of the topsheet, making it easier to leak.
- the mid-high section includes a blood modifying agent that has been found to have at least the effect of reducing blood viscosity and surface tension
- the top sheet is a nonwoven or woven fabric
- menstrual blood is not easily clogged in the cushion portion, and menstrual blood can be quickly transferred from the top sheet to the absorbent body via the cushion portion.
- the absorbent article of the present disclosure has a cushion portion between the top sheet and the absorbent body in the middle and high portions, and therefore the interval between the top sheet and the absorbent body tends to be larger than that of conventional absorbent articles. There is. Therefore, when the middle and high parts contain a blood modifying agent, blood that has reached the top sheet can be quickly transferred to the absorbent body via the cushion part, and therefore it is more difficult to leak.
- a blood modifying agent having an IOB of about 0.00 to about 0.60 is highly organic and easily enters between blood cells, so that it stabilizes the blood cells and makes it difficult to form a monetary structure in the blood cells. .
- the above-mentioned modifying agent stabilizes blood cells and makes it difficult to form a monetary structure on the blood cells, so that the absorbent body can easily absorb menstrual blood.
- SAP an acrylic superabsorbent polymer
- the blood cells that have been collected cover the SAP surface, making it difficult for SAP to exhibit absorption performance.
- the SAP can easily exhibit the absorption performance.
- the blood modifying agent having high affinity for red blood cells protects the red blood cell membrane, the red blood cells are hardly destroyed.
- liquid-permeable top sheet those usually used in the art can be employed without particular limitation, for example, a sheet-like material having a structure that allows blood to pass through, for example, an apertured film, A woven fabric, a nonwoven fabric, etc. are mentioned.
- the fibers constituting the woven fabric and the nonwoven fabric include natural fibers and chemical fibers.
- natural fibers include cellulose such as pulverized pulp and cotton.
- chemical fibers include rayon and fibrillar rayon. And regenerated cellulose, semi-synthetic cellulose such as acetate and triacetate, thermoplastic hydrophobic chemical fibers, and thermoplastic hydrophobic chemical fibers subjected to hydrophilic treatment.
- thermoplastic hydrophobic chemical fiber examples include single fibers such as polyethylene (PE), polypropylene (PP), and polyethylene terephthalate (PET), and fibers made of a graft polymer of PE and PP.
- nonwoven fabric examples include air-through nonwoven fabric, spunbond nonwoven fabric, point bond nonwoven fabric, spunlace nonwoven fabric, needle punch nonwoven fabric, melt blown nonwoven fabric, and combinations thereof (for example, SMS).
- liquid-impermeable back sheet examples include films containing PE, PP, etc., resin films having air permeability, those obtained by bonding a resin film having air permeability to a nonwoven fabric such as spunbond or spunlace, and composite materials such as SMS.
- a layer nonwoven fabric etc. are mentioned.
- a low density polyethylene (LDPE) film having a basis weight of about 15 to about 30 g / m 2 is preferred.
- Constituent elements of the absorbent core include, for example, hydrophilic fibers such as cellulose such as pulverized pulp and cotton, regenerated cellulose such as rayon and fibril rayon, semi-synthetic cellulose such as acetate and triacetate, particulate polymer, and fibrous polymer. , Thermoplastic hydrophobic chemical fibers, hydrophobized thermoplastic hydrophobic chemical fibers, and combinations thereof.
- a superabsorbent polymer for example, a granular material such as sodium acrylate copolymer may be mentioned.
- the core wrap is not particularly limited as long as it is liquid permeable and has a barrier property that does not allow the polymer absorber to permeate, and examples thereof include woven fabric and nonwoven fabric.
- examples of the woven fabric and non-woven fabric include natural fibers, chemical fibers, and tissues.
- the absorbent body As a second example of the absorbent body, one formed from an absorbent sheet or a polymer sheet can be cited, and the thickness is preferably about 0.3 to about 5.0 mm.
- the absorbent sheet and polymer sheet can be used without particular limitation as long as they are usually used in absorbent articles such as sanitary napkins.
- the blood modifying agent can be present at any location, such as the entire surface of the top sheet or the central region near the vaginal opening, with respect to the planar direction of the top sheet.
- the middle and high portions include the blood modifying agent
- the blood modifying agent when the liquid-permeable top sheet is formed from a nonwoven fabric or a woven fabric, the blood modifying agent is provided between the fibers of the nonwoven fabric or the woven fabric.
- the blood modifying agent is preferably adhered to the surface of the non-woven fiber in the form of droplets or particles, or the surface of the fiber can be covered.
- the middle and high portions contain the blood modifying agent
- the blood modifying agent closes the aperture of the apertured film.
- the blood modifying agent can be attached in the form of droplets or particles on the surface of the apertured film, for example. This is because when the blood modifying agent closes the gap between the fibers of the nonwoven fabric or the woven fabric or the aperture of the apertured film, the absorbed liquid may be inhibited from transferring to the absorber.
- the blood modifying agent preferably has a large surface area in order to quickly migrate to absorbed blood, and is present in the form of droplets or particles.
- the blood modifying agent preferably has a small particle size.
- the middle and high portions contain the blood modifying agent
- these are hydrophilic agents. It is preferable that the surface is hydrophilized by coating or mixing. If the original material is hydrophilic, then it has an IOB of about 0.00 to about 0.60 and is coated with a highly organic and lipophilic modifier, so that the lipophilic region and hydrophilic The domain will coexist sparsely. Thereby, a certain absorption performance is exhibited for menstrual blood composed of a hydrophilic component (plasma and the like) and a lipophilic component (blood cell and the like).
- the method for applying the blood modifying agent is not particularly limited, and is heated as necessary, for example, a non-contact coater, for example, a spiral. It can apply
- a non-contact type coater is preferable from the viewpoint that the droplet-like or particulate modifier is uniformly dispersed throughout and the point of not damaging the material.
- the blood modifying agent is applied from the control seam HMA gun as it is when it is liquid at room temperature, or heated to lower the viscosity, and heated so as to be liquefied when it is solid at room temperature. be able to. By increasing the air pressure of the control seam HMA gun, the particulate blood modifying agent can be applied.
- the blood modifying agent can be applied when producing a topsheet material, for example, a nonwoven fabric, or a production line for producing an absorbent article. Can also be applied.
- the middle and high portions contain the blood modifying agent, from the viewpoint of suppressing the capital investment, it is preferable to apply the blood modifying agent in the production line of the absorbent article, and the blood modifying agent falls off. In order to suppress contamination of the line, it is preferable to apply the blood modifying agent downstream of the production line, specifically, immediately before the product is enclosed in the individual package.
- the blood modifying agent may also have an action as a lubricant.
- the top sheet is a nonwoven fabric, the friction between the fibers can be reduced, so that the flexibility of the entire nonwoven fabric is improved.
- a top sheet is a resin film, friction with a top sheet and skin can be reduced.
- the blood modifying agent preferably has a weight average molecular weight of about 2,000 or less, and more preferably has a weight average molecular weight of 1,000 or less. preferable. This is because when the weight average molecular weight increases, it becomes difficult to lower the viscosity of the blood modifying agent to a viscosity suitable for coating, and there is a case where the blood modifying agent should be diluted with a solvent. Moreover, when the weight average molecular weight is increased, the blood modifying agent is tacky, which may cause discomfort to the wearer.
- the absorbent article is suitable for absorbent articles intended to absorb blood, such as sanitary napkins and panty liners.
- an air-through non-woven fabric having a core-sheath structure formed from a polyethylene (PE) sheath and a polyethylene terephthalate (PET) core and made of a hydrophilic treated composite fiber (fineness: 2.2 dtex) Amount: 30 g / m 2 ) was prepared.
- the cushion part before being incorporated into the absorbent article has a shape in which the projection in the thickness direction of the absorbent article is substantially rounded rectangle and the thickness is constant, as shown in FIG.
- the length in the longitudinal direction was 70 mm, and the length in the width direction was 30 mm.
- the compressive force of the cushion part was measured according to the method described in this specification.
- the center part of the width direction of a cushion part rose and it changed into convex shape.
- Blend (basis weight: 250 g / m 2) of the pulp and SAP (90:10, weight ratio), tissue (basis weight: 14 g / m 2) wound in a plurality of rhombus as shown in FIGS. 6 (a)
- the squeezed portion is formed at an interval of about 0.4 mm to form a folding shaft and cut into the shape shown in FIG. 6A (length in the longitudinal direction: about 150 mm). )did.
- both two diagonal lines were about 0.7 mm.
- a film containing PE (basis weight: 23 g / m 2 ) coated with an adhesive was prepared.
- the absorbent body, the cushion part, and the top sheet were laminated in order, and the absorbent body and the top sheet were squeezed to form a middle and high part as shown in FIGS.
- the absorbent article and the back sheet are bonded and cut as shown in FIGS. 1-1 was produced.
- Absorbent article no. In 1-1 the length of the middle-high portion in the longitudinal direction was about 70 mm, and the length of the middle-high portion in the width direction was about 35 mm. Also, the absorbent article No. The longitudinal length of 1-1 was about 176 mm, and the length in the width direction was about 80 mm.
- Example 1 Absorbent article no. 1-1-No. Prepare 1-8 each, and have multiple subjects wear them, and evaluated the bendability and recoverability from the folded absorbent article according to the following criteria: . ⁇ : No problem in bending and recovery. X: There was a problem in bendability and / or recoverability. The results are shown in Table 2 below.
- the cushion portion had an arch shape as shown in FIGS. 4 and 5 due to the tensile force between the compressed top sheet and the absorbent body. Therefore, since the thickness of the outer peripheral part of the middle-high part is thinner than the thickness of the middle part of the middle-high part, the cushion part has a density of the cushion part in the middle part of the middle-high part. It is clear that it is higher.
- Panacet 810s manufactured by NOF Corporation, triester of glycerin and fatty acid
- the absorbent article No By applying Panacet 810s at a basis weight of 5.0 g / m 2 from the control seam HMA gun at room temperature, centering on the middle and high portions of 1-4, the absorbent article No. 2-1.
- panacet 810s When confirmed with an electron microscope, panacet 810s was in the form of fine particles and adhered to the surface of the fibers of the top and middle portions of the top sheet.
- Example 2 Absorbent article no. When 10 subjects wore 1-4, a total of 20 tests were answered that there was little leakage. In addition, both dry and wet, it deformed following the movement of the leg and got an answer that it had excellent fit. Next, the absorbent article No. As a result of having 10 subjects wear 2-1, the absorbent article no. Compared with 1-4, there was a reply that the area of surface contamination was small and leakage was small.
- Example 3 [Other blood modifying agent data] A commercially available sanitary napkin was prepared.
- the sanitary napkin includes a top sheet formed from an air-through nonwoven fabric (composite fiber made of polyester and polyethylene terephthalate, basis weight: 35 g / m 2 ) treated with a hydrophilic agent, and an air-through nonwoven fabric (composite made of polyester and polyethylene terephthalate).
- Second sheet formed from fibers, basis weight: 30 g / m 2 ), pulp (basis weight: 150 to 450 g / m 2 , more in the center), acrylic superabsorbent polymer (basis weight: 15 g / m 2 ) And an absorbent body containing a tissue as a core wrap, a side sheet treated with a water repellent, and a back sheet made of a polyethylene film.
- fatty acids manufactured by NOF Corporation C 8 fatty to C 10 are contained in approximately 85:15 weight ratio of triesters of glycerol with fatty acids, the weight average molecular weight: about 480 ⁇ Panasate 800, manufactured by NOF Corporation All fatty acids are octanoic acid (C 8 ), triester of glycerin and fatty acid, weight average molecular weight: about 470
- Panaceate 800B manufactured by NOF Corporation All fatty acids are 2-ethylhexanoic acid (C 8 ), triester of glycerin and fatty acid, weight average molecular weight: about 470 ⁇ NA36, manufactured by NOF Corporation C 16 fatty acid: fatty acid C 18: (including both saturated and unsaturated fatty acids) C 20 fatty acid approximately 5: contained at a weight ratio of 3: 92 Triester of glycerin and fatty acid, weight average molecular weight: about 880
- C 8 fatty C 10: fatty acid
- C 12 fatty acid
- C 14 (including both saturated and unsaturated fatty acids)
- C 16 is approximately 4 : Triester of glycerin and fatty acid, contained in a mass ratio of 8: 60: 25: 3, weight average molecular weight: 670 -Caprylic acid diglyceride, manufactured by NOF Corporation
- Fatty acid is octanoic acid, diester of glycerin and fatty acid, weight average molecular weight: 340
- Uniol PB1000R polybutylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1000 [(E 2 ) ester of polyoxy C 2 -C 6 alkylene glycol and at least one fatty acid] -Wilbright cp9, manufactured by NOF Co., Ltd.
- Uniol TG-3000 manufactured by NOF Corporation Polyglycol glycol glyceryl ether, about 16 repeating units, weight average molecular weight: about 3,000 ⁇ Uniol TG-4000, glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 4,000
- [Other materials] -NA50 manufactured by NOF Corporation Hydrogen added to NA36 to reduce the ratio of double bonds derived from the unsaturated fatty acid as a raw material Triester of glycerin and fatty acid, weight average molecular weight: about 880 -(Caprylic acid / capric acid) monoglyceride, NOF Corporation octanoic acid (C 8 ) and decanoic acid (C 10 ) in a mass ratio of approximately 85:15, monoester of glycerin and fatty acid, Weight average molecular weight: about 220 -Monomuls 90-L2 lauric acid monoglyceride, manufactured by Cognis Japan
- PEG 1500 manufactured by NOF Corporation, polyethylene glycol, weight average molecular weight: about 1,500 to about 1,600 Nonionic S-6, polyoxyethylene monostearate manufactured by NOF Corporation, about 7 repeating units, weight average molecular weight: about 880 -Wilbright s753, NOF Corporation polyoxyethylene polyoxypropylene polyoxybutylene glycerin, weight average molecular weight: about 960
- the IOB, melting point and water solubility of the sample are shown in Table 3 below.
- the water solubility was measured according to the method described above, but 20.0 g was added to 100 g of demineralized water, and the sample dissolved after 24 hours was evaluated as “20 g ⁇ ”. Samples that dissolved 0.05 g but did not dissolve 1.00 g were evaluated as 0.05 to 1.00 g.
- “ ⁇ 45” means that the melting point is less than 45 ° C.
- the skin contact surface of the top sheet of the sanitary napkin was coated with the blood modifying agent described above.
- Each blood modifying agent is heated as it is if the blood modifying agent is liquid at room temperature, and if the blood modifying agent is solid at room temperature, it is heated to melting point + 20 ° C., and then control seam HMA gun
- Each blood modifying agent was atomized and applied to the entire skin contact surface of the top sheet so that the basis weight was approximately 5 g / m 2 .
- FIG. 10 is an electron micrograph of the skin contact surface of the top sheet in a sanitary napkin (No. 3-5) in which the top sheet contains tri-C2L oil fatty acid glycerides. As is clear from FIG. 10, the tri-C2L oil fatty acid glyceride is in the form of fine particles and adheres to the fiber surface.
- Rewetting rate (%) 100 ⁇ (filter paper mass after test ⁇ initial filter paper mass) / 6
- absorption body transfer rate which is the time for blood to transfer from the top sheet to the absorber, was measured after the second drop of blood.
- absorption body transfer speed means the time from when blood is introduced into the top sheet until the redness of blood is not seen on the surface and inside of the top sheet.
- the whiteness of the skin contact surface of the top sheet after the absorber transfer speed test was visually evaluated according to the following criteria.
- the rewetting rate was 22.7% and the absorber transfer rate was more than 60 seconds, but all triesters of glycerin and fatty acids had a rewetting rate. Since it is 7.0% or less and the absorber transfer speed is 8 seconds or less, it can be seen that the absorption performance is greatly improved. However, among the triesters of glycerin and fatty acid, NA50 having a melting point exceeding 45 ° C. did not significantly improve the absorption performance.
- a blood modifying agent having an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C. or less, and a water solubility of about 0.00 to about 0.05 g for 100 g of water at 25 ° C. It was found that the absorption performance was greatly improved.
- No. 3-1 When a plurality of volunteer subjects wore the sanitary napkin of 3-47, no. 3-1. In the sanitary napkin containing 3-32 blood modifying agent, even after absorbing menstrual blood, the top sheet was not sticky and the answer was that the top sheet was smooth.
- Example 3 is an example in which the sanitary napkin does not have a predetermined middle and high part, no. 3-1.
- No. 3-32 sanitary napkin is No. 3 containing panacet 810s. Since a result equivalent to 3-7 was obtained, no. 3-1.
- the blood modifying agent used in the sanitary napkin No. 3-32 was used as an absorbent article no. When applied to 1-4, the absorbent article No. 1 coated with the blood modifying agent (Panasate 810s) was used. It is considered that a result equivalent to 2-1 is obtained.
- Example 4 The rewetting rate was evaluated according to the procedure described above for various animal blood.
- the blood used in the experiment is as follows. [Animal species] (1) Human (2) Horse (3) Sheep
- Defibrinated blood After collecting blood, stirred for about 5 minutes in an Erlenmeyer flask with glass beads
- ⁇ EDTA blood 65 mL of venous blood plus 0.5 mL of 12% EDTA / 2K physiological saline
- Serum or plasma supernatant after centrifuging defibrinated blood or EDTA blood, respectively, at room temperature at about 1900 G for 10 minutes.
- Blood cell serum is removed from the blood, and the residue is phosphate buffered saline (PBS ) Washed twice and then added with phosphate buffered saline for the removed serum
- An absorbent article was produced in the same manner as in Example 3 except that the tri-C2L oil fatty acid glyceride was applied so that the basis weight was approximately 5 g / m 2, and the rewetting rate was evaluated for the various blood types described above. . The measurement was performed 3 times for each blood, and the average value was adopted. The results are shown in Table 4 below.
- Example 3 The same tendency as the equine EDTA blood obtained in Example 3 was also obtained in human and sheep blood. Similar trends were also observed in defibrinated blood and EDTA blood.
- Tri C2L oil fatty acid glyceride is applied to the skin contact surface of the top sheet formed from an air-through nonwoven fabric (a composite fiber composed of polyester and polyethylene terephthalate, basis weight: 35 g / m 2 ) using a control seam HMA gun. It is atomized and applied so that the basis weight is approximately 5 g / m 2 . Moreover, the thing which has not apply
- the mass (c) of the top sheet containing the cell strainer + horse EDTA blood is measured.
- the post-test absorption amount (g) per 1 g of the top sheet is calculated according to the following formula.
- Absorption after test [mass (c) ⁇ mass (a)] / 0.2 (9)
- the top sheet containing a blood modifying agent has low blood retention and can be quickly transferred to an absorber after absorbing blood.
- Example 6 [Viscosity of blood containing blood modifying agents] The viscosity of blood containing a blood modifying agent was measured using a Rheometric Expansion System ARES (Rheometric Scientific, Inc). 2% by mass of panacet 810s was added to equine defibrinated blood, lightly stirred to form a sample, the sample was placed on a parallel plate with a diameter of 50 mm, the gap was 100 ⁇ m, and the viscosity was measured at 37 ⁇ 0.5 ° C. . Because of the parallel plate, the sample did not have a uniform shear rate, but the average shear rate displayed on the instrument was 10 s ⁇ 1 .
- the viscosity of equine defibrinated blood containing 2% by mass of panacet 810s was 5.9 mPa ⁇ s, while the viscosity of equine defibrinated blood containing no blood modifying agent was 50.4 mPa ⁇ s. Therefore, it can be seen that equine defibrinated blood containing 2% by mass of panacet 810s decreases the viscosity by about 90% compared to the case where no blood modifying agent is contained.
- blood is known to contain components such as blood cells and have thixotropic properties, it is suggested that the blood modifying agent of the present disclosure can lower blood viscosity in a low viscosity region. By reducing the viscosity of blood, absorbed menstrual blood can be quickly transferred from the top sheet to the absorber.
- Example 7 [Micrograph of blood containing blood modifying agent] A healthy volunteer's menstrual blood is collected on a food protective wrap film, and a portion of the panacet 810s dispersed in 10 times the mass of phosphate buffered saline is used, and the concentration of panacet 810s is 1% by mass.
- Menstrual blood was appropriately applied to a slide glass, covered with a cover glass, and the state of red blood cells was observed with an optical microscope.
- a photomicrograph of menstrual blood containing no blood modifying agent is shown in FIG. 11 (a)
- a photomicrograph of menstrual blood containing panacet 810s is shown in FIG. 11 (b).
- red blood cells form a collective mass such as remuneration, but in menstrual blood that includes panacet 810s, It can be seen that it is stably dispersed. Therefore, it is suggested that the blood modifying agent functions to stabilize red blood cells in the blood.
- Example 8 [Surface tension of blood containing blood modifying agents]
- the surface tension of blood containing a blood modifying agent was measured by a pendant drop method using a contact angle meter Drop Master 500 manufactured by Kyowa Interface Science Co., Ltd.
- the surface tension was measured after adding a predetermined amount of blood modifying agent to sheep defibrinated blood and shaking sufficiently. Although the measurement is automatically performed by the instrument, the surface tension ⁇ is obtained by the following equation (see FIG. 12).
- the density ⁇ is defined in 5. of “Density Test Method and Density / Mass / Capacity Conversion Table” of JIS K 2249-1995. Based on the vibration density test method, the temperature was measured as shown in Table 6 below. For measurement, DA-505 of Kyoto Electronics Industry Co., Ltd. was used. The results are shown in Table 6.
- the blood modifying agent has a water solubility of about 0.00 to about 0.05 g in 100 g of water at 25 ° C., but the solubility in water is very low. It can be seen that the surface tension of blood can be lowered. By reducing the surface tension of blood, the absorbed blood can be quickly transferred to the absorbent body without being held between the fibers of the top sheet.
- the present invention relates to the following J1 to J15.
- An absorbent article comprising a liquid-permeable top sheet, a liquid-impermeable back sheet, and an absorbent body between the liquid-permeable top sheet and the liquid-impermeable back sheet,
- the absorbent article has a middle and high portion protruding in the thickness direction of the absorbent article in the excretory opening contact area,
- the middle-high part includes a part of the top sheet and a cushion part disposed between the top sheet and the absorbent body,
- the cushion part has a maximum thickness of 3 to 30 mm
- the absorbent body has one or more compressed parts formed by continuously or intermittently pressing the absorbent body in the longitudinal direction of the absorbent article, and the one or more compressed parts. However, it forms a folding shaft for bending the absorbent article so that the skin contact surface of the top sheet protrudes in the width direction thereof.
- the said absorbent article characterized by the above-mentioned.
- the middle-high portion further includes a blood modifying agent having an IOB of 0.00 to 0.60, a melting point of 45 ° C. or lower, and a water solubility of 0.00 to 0.05 g with respect to 100 g of water at 25 ° C.
- the blood modifying agent comprises the following (i) to (iii): (I) hydrocarbons, (Ii) from (ii-1) a hydrocarbon moiety and (ii-2) a carbonyl group (—CO—) and an oxy group (—O—) inserted between the CC single bonds of the hydrocarbon moiety.
- —COOH carboxyl group
- —OH hydroxyl group
- the blood modifying agent comprises the following (i ′) to (iii ′), (I ′) hydrocarbon, (Ii ′) (ii′-1) a hydrocarbon moiety and (ii′-2) a carbonyl bond (—CO—), an ester bond (—COO) inserted between the C—C single bonds of the hydrocarbon moiety.
- the blood modifying agent comprises the following (A) to (F), (A) (A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the chain An ester with a compound having one carboxyl group for substituting a hydrogen atom in the hydrocarbon moiety, (B) (B1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the chain An ether with a compound having one hydroxyl group replacing a hydrogen atom of the hydrocarbon moiety, (C) (C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing a chain hydrocarbon moiety and 2 to 4 carboxyl groups replacing a hydrogen atom in the chain hydrocarbon moiety; C2) an ester of a compound having a chain hydrocarbon mo
- the blood modifying agent comprises (a 1 ) an ester of a chain hydrocarbon tetraol and at least one fatty acid, (a 2 ) an ester of a chain hydrocarbon triol and at least one fatty acid, (a 3 ) a chain An ester of a hydrocarbon diol and at least one fatty acid, (b 1 ) an ether of a chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol, (b 2 ) a chain hydrocarbon triol and at least one aliphatic Ethers with monohydric alcohols, (b 3 ) ethers of chain hydrocarbon diols with at least one aliphatic monohydric alcohol, (c 1 ) chain hydrocarbon tetracarboxylic acids having 4 carboxyl groups, hydroxy acids , alkoxy acid or an oxo acid, at least one ester of an aliphatic monohydric alcohol, (c 2) a chain hydrocarbon tricaprate with 3 carboxyl groups
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Fluid Mechanics (AREA)
- Dermatology (AREA)
- Absorbent Articles And Supports Therefor (AREA)
Abstract
Description
特許文献1に記載の吸収性物品は、以下の構成を有する:液透過性の表面シート、液不透過性の裏面シート、及びこれら両シート間に介在された液保持性の吸収体を具備し、実質的に縦長に形成された吸収性物品であって、前記吸収体は、その幅方向中央部における裏面シート側の面に凹部を有すると共に、該凹部の両側に位置する部分の表面シート側の面に、長手方向に延びる一対の溝を有しており、前記凹部は、前記吸収体の構成材料の坪量を他の部分より減らして形成されており、該凹部の幅が5~30mmである吸収性物品。
また、特許文献1の[0015]には、上記吸収体が、パルプ繊維を主体として構成されることが記載されている。
従って、本開示は、経血を吸収する前のドライ時と、経血を吸収した後のウェット時との両方において、着用者の脚の動きに追従して変形し、そして元の形状に戻ることができ、フィット性に優れる吸収性物品を提供することを目的とする。
図1~5に、本開示の実施形態の1つに従う吸収性物品を示す。図1は、本開示の実施形態の1つに従う吸収性物品の斜視図である。図1に示される吸収性物品1は、生理用ナプキンである。図1に示される吸収性物品1では、向かって右奥が着用者の前方に相当し、そして向かって左手前が着用者の後方に相当するが、図1に示される吸収性物品1は、おおむね、前後対称且つ左右対称の形状を有する。
なお、図1に示される吸収性物品1では、トップシート4が、肌当接面に、長手方向に延びる、複数の畝溝構造を有しており、図1では、便宜上、畝と溝との境界が、実線で示されている。図1に示される吸収性物品1では、2本の実線で囲まれた幅の広い領域が畝部を意味し、そして2本の実線で囲まれた幅の狭い領域が溝部を意味し、図1に示される吸収性物品1では、複数の畝部と、複数の溝部とが、吸収性物品1の幅方向に交互に配置されている。
また、本明細書において、「中高部」は、トップシートの一部と、クッション部とを含む部分を意味し、そして中高部では、その頂部から外縁に向かって厚さが概ね薄くなる。
なお、本明細書において、吸収性物品が、折り軸を起点に、その幅方向に且つトップシートの肌当接面が突出するように折り曲げることを、「凸状変形する」と称する場合があり、そしてその状態を「凸状変形」と称する場合がある。
上記熱可塑性化学繊維の原料としては、ポリエチレン(PE)、ポリプロピレン(PP)、ポリエチレンテレフタレート(PET)、PE及びPPのグラフトポリマー等が挙げられ、そして上記熱可塑性化学繊維の繊維タイプの例としては、単繊維、複合繊維、熱収縮繊維、熱伸長性繊維、異型繊維、立体捲縮繊維、分割繊維等が挙げられる。
上記繊維は、経血等の入り込みやすさ、肌触り等を考慮すると、約1.1~約8.8dtexの繊度を有することが好ましい。
なお、上記クッション部の最大厚さは、吸収性物品から取り出したクッション部ではなく、吸収性物品の状態における、クッション部の最大厚さを意味する。
さらに、図7に示される吸収性物品1では、吸収体7が、バックシート8側に、折り軸14に沿った溝部16を有し、バックシート8が、溝部16に沿って窪んでいる。バックシートが、吸収体の溝部に沿って窪むことにより、吸収性物品が、より凸状変形しやすくなる。
例えば、トップシートと、クッション部と、折り軸に沿った溝部を有する吸収体とから成る積層物の上に、バックシートを貼り付ける場合には、積層物を(製造すべき吸収性物品の)長手方向に搬送しながら、積層すべきバックシートを、ラインのテンションを下げて積層物の上に積層することにより、バックシートを、吸収体の溝部に沿って窪ませることができる。なお、上記積層物は、圧搾、ホットメルト等により接着されている。
さらに、吸収体及びバックシートを一緒に圧搾することにより、吸収体の折り軸を形成し且つバックシートを、吸収体の溝部に沿って窪ませることができる。
本開示の吸収性物品では、吸収体が折り軸を有するため、着用者が脚を閉じた場合等、吸収性物品が、幅方向から圧縮を受けた場合に、折り軸を起点に、吸収性物品の幅方向に且つトップシートの肌当接面が突出するように折り曲がることができる。
なお、本明細書において、「平均坪量」は、試料(例えば、クッション部、吸収体等)の質量を、その面積で除した、試料全体の坪量を意味する。
図8は、圧縮力を測定する装置の例を示す概略図である。図8(a)は、圧縮力測定装置21を上から見た図であり、そして図8(b)は、圧縮力測定装置21を側面から見た図である。図8に示される圧縮力測定装置21は、スタンド22の上の、左右に往復運動することが可能な稼働台23と、稼働台23の上に設置された、圧縮力を測定するデジタルフォースゲージ24と、測定すべき試料を載せる試料台25とを有する。試料台25には、測定すべき試料26と、着用者の脚に見立て、そして試料26を挟むように配置される2つの円柱形の圧縮パーツ27と、圧縮パーツの一方を固定するためのストッパー28が配置されている。
少なくともトップシート及び吸収体を、圧搾されたトップシートと吸収体との引張力によりクッション部の外縁が圧縮され且つその厚さが薄くなるように圧搾することにより、中高部の外周部におけるクッション部の密度を、中高部の中央部におけるクッション部の密度よりも高くすることができる。一方、中高部の中央部では、クッション部の圧縮度が低く、その厚さが外周部ほど薄くならないため、クッション部の密度が高くなりにくい。
なお、クッション部に関する「中心」は、吸収性物品の長手方向及び幅方向の中心を意味する。
さらに、上記クッション部は、その坪量が場所によって異なっていてもよい。
(1)2次元レーザー変位計を用いて、測定すべき位置のクッション部の厚さt(cm)を測定する。上記2次元レーザー変位計としては、例えば、キーエンス株式会社製 高精度2次元レーザー変位計 LJ-Gシリーズ(型式:LJ-G030)が挙げられる。なお、測定すべき位置のクッション部の厚さは、測定すべき位置の吸収性物品の厚さから、クッション部の存在しない領域の厚さを減ずることにより算出する。
(3)密度d(g/cm3)を、下記式:
d=b/(10,000×t)
に従って算出する。
なお、EDTA血については、後述する。
本発明の別の実施形態に従う吸収性物品では、液透過性のトップシートが、複数のピン開孔部を有する。
また、本開示の吸収性物品は、着用者の排泄口、特に、小陰唇にフィットし、漏れを生じさせにくいため、そのサイズを小さくすることができ、本開示の吸収性物品は、好ましくは約100~約500mm、より好ましくは約120~約350mm、そしてさらに好ましくは約150~約250mmの長手方向の長さと、好ましくは約40~約200mm、より好ましくは約45~約180mm、そしてさらに好ましくは約50~100mmの幅方向の長さとを有する。
なお、本明細書では、吸収体の幅方向に関する「中央領域」は、吸収体の幅方向中心から、吸収体の幅方向端部までの距離の0~20%の領域を意味する。
IOB(Inorganic Organic Balance)は、親水性及び親油性のバランスを示す指標であり、本明細書では、小田らによる次式:
IOB=無機性値/有機性値
により算出される値を意味する。
藤田氏による、主要な基の有機性値及び無機性値を、下記表1にまとめる。
本開示の吸収性物品が、人体に接して用いられることを考慮すると、上記蒸気圧は、40℃(1気圧)で約0~約700Paであることが好ましく、約0~約100Paであることがより好ましく、そして約0~約10Paであることがさらに好ましく、約0~約1Paであることがさらにいっそう好ましく、そして約0.0~約0.1Paであることがさらにいっそう好ましい。蒸気圧が高いと、保存中に気化し、血液改質剤の量の減少、着用時の臭気等の問題が発生する場合があるからである。
また、吸収性物品が長時間にわたって使用される場合には、血液改質剤の融点は、45℃以下の範囲で高い方が好ましい。汗、着用時の摩擦等の影響を受けにくく、長時間着用した場合であっても、血液改質剤が移動しにくいからである。
なお、本明細書では、水溶解度に関して、「溶解」には、試料が脱イオン水に完全に溶解し、均一混合物を形成した場合と、試料が完全にエマルション化した場合とが含まれる。なお、「完全」とは、脱イオン水に、試料の塊が存在しないことを意味する。
Mw=ΣNiMi 2/ΣNiMi
により求められるMwを意味する。
GPCの測定条件としては、例えば、以下が挙げられる。
機種:(株)日立ハイテクノロジーズ製 高速液体クロマトグラム Lachrom Elite
カラム:昭和電工(株)製 SHODEX KF-801、KF-803及びKF-804
溶離液:THF
流量 :1.0mL/分
打込み量:100μL
検出:RI(示差屈折計)
なお、本明細書の実施例に記載される重量平均分子量は、上記条件により測定したものである。
(i)炭化水素、
(ii) (ii-1)炭化水素部分と、(ii-2)上記炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、及び
(iii) (iii-1)炭化水素部分と、(iii-2)上記炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基と、(iii-3)上記炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
並びにそれらの任意の組み合わせから成る群から選択される。
上記鎖状炭化水素には、直鎖状炭化水素及び分岐鎖状炭化水素が含まれる。
(i’)炭化水素、
(ii’) (ii’-1)炭化水素部分と、(ii’-2)上記炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合とを有する化合物、及び
(iii’) (iii’-1)炭化水素部分と、(iii’-2)上記炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合と、(iii’-3)上記炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
並びにそれらの任意の組み合わせから成る群から選択される。
(A) (A1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(A2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のカルボキシル基とを有する化合物とのエステル、
(B) (B1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(B2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエーテル、
(C) (C1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する、2~4個のカルボキシル基とを含むカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、(C2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエステル、
(D)鎖状炭化水素部分と、上記鎖状炭化水素部分のC-C単結合間に挿入された、エーテル結合(-O-)、カルボニル結合(-CO-)、エステル結合(-COO-)、及びカーボネート結合(-OCOO-)から成る群から選択されるいずれか1つの結合とを有する化合物、
(E)ポリオキシC2~C6アルキレングリコール、又はそのエステル若しくはエーテル、及び
(F)鎖状炭化水素、
並びにそれらの任意の組み合わせから成る群から選択される。
以下、(A)~(F)に従う血液改質剤について詳細に説明する。
(A) (A1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(A2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のカルボキシル基とを有する化合物とのエステル(以下、「化合物(A)」と称する場合がある)は、上述のIOB、融点及び水溶解度を有する限り、全てのヒドロキシル基がエステル化されていなくともよい。
上記鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステルとしては、例えば、次の式(1):
(式中、R1~R4は、それぞれ、鎖状炭化水素である)
また、上記ペンタエリトリトールと脂肪酸とのエステルとしては、IOBを小さくし、より疎水性とするために、ジエステル、トリエステル又はテトラエステルであることが好ましく、トリエステル又はテトラエステルであることがより好ましく、そしてテトラエステルであることがさらに好ましい。
なお、上記計算に当たっては、二重結合、三重結合、iso分岐、及びtert分岐の影響は、考慮していない。
上記鎖状炭化水素トリオールと少なくとも1の脂肪酸とのエステルとしては、例えば、次の式(5):
のグリセリンと脂肪酸とのモノエステルが挙げられる。
上記グリセリンと脂肪酸とのトリエステルは、いわゆる、脂肪であり、人体を構成しうる成分であるため、安全性の観点から好ましい。
上記グリセリンと脂肪酸とのモノエステルでは、グリセリンと脂肪酸とのモノエステルを構成する脂肪酸の炭素数、すなわち、式(7)において、R5C部分の炭素数が19の場合にIOBが0.59となる。従って、上記グリセリンと脂肪酸とのモノエステルでは、脂肪酸の炭素数が約19以上である場合に、IOBが約0.00~約0.60の要件を満たす。
上記鎖状炭化水素ジオールと少なくとも1の脂肪酸とのエステルとしては、例えば、C2~C6の鎖状炭化水素ジオール、例えば、C2~C6のグリコール、例えば、エチレングリコール、プロピレングリコール、ブチレングリコール、ペンチレングリコール又はヘキシレングリコールと、脂肪酸とのモノエステル又はジエステルが挙げられる。
R8COOCkH2kOCOR9 (8)
(式中、kは、2~6の整数であり、そしてR8及びR9は、それぞれ、鎖状炭化水素である)
のC2~C6グリコールと脂肪酸とのジエステル、及び次の式(9):
R8COOCkH2kOH (9)
(式中、kは、2~6の整数であり、そしてR8は、鎖状炭化水素である)
のC2~C6グリコールと脂肪酸とのモノエステルが挙げられる。
上記C2~C6グリコールと脂肪酸とのエステルの市販品としては、例えば、コムポールBL、コムポールBS(以上、日油株式会社製)等が挙げられる。
(B) (B1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(B2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエーテル(以下、「化合物(B)」と称する場合がある)は、上述のIOB、融点及び水溶解度を有する限り、全てのヒドロキシル基がエーテル化されていなくともよい。
の、ペンタエリトリトールと脂肪族1価アルコールとのテトラエーテル、トリエーテル、ジエーテル及びモノエーテルが挙げられる。
の、グリセリンと脂肪族1価アルコールとのトリエーテル、ジエーテル及びモノエーテルが挙げられる。
R17OCnH2nOR18 (17)
(式中、nは、2~6の整数であり、そしてR17及びR18は、それぞれ、鎖状炭化水素である)
のC2~C6グリコールと脂肪族1価アルコールとのジエーテル、及び次の式(18):
R17OCnH2nOH (18)
(式中、nは、2~6の整数であり、そしてR17は、鎖状炭化水素である)
のC2~C6グリコールと脂肪族1価アルコールとのモノエーテルが挙げられる。
(C) (C1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する、2~4個のカルボキシル基とを含むカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、(C2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエステル(以下、「化合物(C)」と称する場合がある)は、上述のIOB、融点及び水溶解度を有する限り、全てのカルボキシル基がエステル化されていなくともよい。
(C2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物としては、「化合物(B)」の項で列挙されるもの、例えば、脂肪族1価アルコールが挙げられる。
化合物(C)の例としては、アジピン酸ジオクチル、O-アセチルクエン酸トリブチル等が挙げられ、そして市販されている。
(D)鎖状炭化水素部分と、上記鎖状炭化水素部分のC-C単結合間に挿入された、エーテル結合(-O-)、カルボニル結合(-CO-)、エステル結合(-COO-)、及びカーボネート結合(-OCOO-)から成る群から選択されるいずれか1つの結合とを有する化合物(以下、「化合物(D)」と称する場合がある)としては、(d1)脂肪族1価アルコールと脂肪族1価アルコールとのエーテル、(d2)ジアルキルケトン、(d3)脂肪酸と脂肪族1価アルコールとのエステル、及び(d4)ジアルキルカーボネートが挙げられる。
上記脂肪族1価アルコールと脂肪族1価アルコールとのエーテルとしては、次の式(19):
R19OR20 (19)
(式中、R19及びR20は、それぞれ、鎖状炭化水素である)
を有する化合物が挙げられる。
上記ジアルキルケトンとしては、次の式(20):
R21COR22 (20)
(式中、R21及びR22は、それぞれ、アルキル基である)
を有する化合物が挙げられる。
上記ジアルキルケトンは、市販されている他、公知の方法、例えば、第二級アルコールを、クロム酸等で酸化することにより得ることができる。
上記脂肪酸と脂肪族1価アルコールとのエステルとしては、例えば、次の式(21):
R23COOR24 (21)
(式中、R23及びR24は、それぞれ、鎖状炭化水素である)
を有する化合物が挙げられる。
上記ジアルキルカーボネートとしては、次の式(22):
R25OC(=O)OR26 (22)
(式中、R25及びR26は、それぞれ、アルキル基である)
を有する化合物が挙げられる。
水溶解度を考慮すると、R25及びR26の炭素数の合計が約7以上であることが好ましく、そして約9以上であることがより好ましい。
上記ジアルキルカーボネートは、市販されている他、ホスゲンとアルコールとの反応、塩化ギ酸エステルとアルコール又はアルコラートとの反応、及び炭酸銀とヨウ化アルキルとの反応により合成することができる。
上記ポリオキシC2~C6アルキレングリコール、又はそのエステル若しくはエーテル(以下、化合物(E)と称する場合がある)としては、(e1)ポリオキシC2~C6アルキレングリコール、(e2)ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪酸とのエステル、(e3)ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪族1価アルコールとのエーテル、(e4)ポリオキシC2~C6アルキレングリコールと、鎖状炭化水素テトラカルボン酸、鎖状炭化水素トリカルボン酸、又は鎖状炭化水素ジカルボン酸とのエステル、及び(e5)ポリオキシC2~C6アルキレングリコールと、鎖状炭化水素テトラオール、鎖状炭化水素トリオール、又は鎖状炭化水素ジオールとのエーテルが挙げられる。以下、説明する。
上記ポリオキシC2~C6アルキレングリコールは、i)オキシC2~C6アルキレン骨格、すなわち、オキシエチレン骨格、オキシプロピレン骨格、オキシブチレン骨格、オキシペンチレン骨格、及びオキシヘキシレン骨格から成る群から選択されるいずれか1種の骨格を有し且つ両末端にヒドロキシ基を有するホモポリマー、ii)上記群から選択される2種以上の骨格を有し且つ両末端にヒドロキシ基を有するブロックコポリマー、又はiii)上記群から選択される2種以上の骨格を有し且つ両末端にヒドロキシ基を有するランダムコポリマーを意味する。
HO-(CmH2mO)n-H (23)
(式中、mは2~6の整数である)
により表わされうる。
以上より、式(23)において、mは、約3~約6であり、そして約4~約6であることがより好ましく、そしてnは2以上である。
例えば、式(23)がポリプロピレングリコール(m=3のホモポリマー)である場合には、n=12の場合に、IOBが0.58となる。従って、式(23)がポリプロピレングリコール(m=3のホモポリマー)である場合には、m≧約12の場合に、上記IOBの要件を満たす。
また、式(23)がポリブチレングリコール(m=4のホモポリマー)である場合には、n=7の場合に、IOBが0.57となる。従って、式(23)がポリブチレングリコール(m=4のホモポリマー)である場合には、n≧約7の場合に、上記IOBの要件を満たす。
上記ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪酸とのエステルとしては、「(e1)ポリオキシC2~C6アルキレングリコール」の項で説明したポリオキシC2~C6アルキレングリコールのOH末端の一方又は両方が、脂肪酸によりエステル化されているもの、すなわち、モノエステル及びジエステルが挙げられる。
上記ポリオキシC2~C6アルキレングリコールと脂肪酸とのエステルの市販品としては、例えば、ウィルブライトcp9(日油株式会社製)が挙げられる。
上記ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪族1価アルコールとのエーテルとしては、「(e1)ポリオキシC2~C6アルキレングリコール」の項で説明したポリオキシC2~C6アルキレングリコールのOH末端の一方又は両方が、脂肪族1価アルコールによりエーテル化されているもの、すなわち、モノエーテル及びジエーテルが挙げられる。
上記ポリオキシC2~C6アルキレングリコールと、鎖状炭化水素テトラカルボン酸、鎖状炭化水素トリカルボン酸、又は鎖状炭化水素ジカルボン酸とのエステルにおいて、エステル化すべきポリオキシC2~C6アルキレングリコールとしては、「(e1)ポリオキシC2~C6アルキレングリコール」の項で説明したポリオキシC2~C6アルキレングリコールが挙げられる。また、エステル化すべき鎖状炭化水素テトラカルボン酸、鎖状炭化水素トリカルボン酸、及び鎖状炭化水素ジカルボン酸としては、「化合物(C)」の項で説明されるものが挙げられる。
上記ポリオキシC2~C6アルキレングリコールと、鎖状炭化水素テトラオール、鎖状炭化水素トリオール、又は鎖状炭化水素ジオールとのエーテルにおいて、エーテル化すべきポリオキシC2~C6アルキレングリコールとしては、「(e1)ポリオキシC2~C6アルキレングリコール」の項で説明したポリオキシC2~C6アルキレングリコールが挙げられる。また、エーテル化すべき鎖状炭化水素テトラオール、鎖状炭化水素トリオール、及び鎖状炭化水素ジオールとしては、「化合物(A)」の項で説明されるもの、例えば、ペンタエリトリトール、グリセリン、及びグリコールが挙げられる。
ユニルーブ(商標)5TP-300KBは、ペンタエリトリトール1モルに、プロピレングリコール65モルと、エチレングリコール5モルとを重縮合させた化合物であり、そのIOBは0.39であり、融点は45℃未満であり、そして水溶解度は0.05g未満であった。
ユニオール(商標)TG-4000は、グリセリン1モルに、プロピレングリコール70モルを重縮合させた化合物であり、そのIOBは0.40であり、融点は45℃未満であり、水溶解度は0.05g未満であり、そして重量平均分子量は約4,000であった。
上記鎖状炭化水素は、上記無機性値が0であることから、IOBが0.00であり、そして水溶解度がほぼ0gであるので、融点が約45℃以下のものであれば、上記血液改質剤に含まれうる。上記鎖状炭化水素としては、例えば、(f1)鎖状アルカン、例えば、直鎖アルカン及び分岐鎖アルカンが挙げられ、例えば、直鎖アルカンの場合には、融点が約45℃以下であることを考慮すると、おおむね、炭素数が22以下のものが含まれる。また、蒸気圧を考慮すると、おおむね、炭素数が13以上のものが含まれる。分岐鎖アルカンの場合には、直鎖アルカンよりも、同一炭素数において、融点が低くなる場合があるため、炭素数が22以上のものも含まれうる。
上記炭化水素の市販品としては、例えば、パールリーム6(日油株式会社)が挙げられる。
上記不織布の例としては、例えば、エアスルー不織布、スパンボンド不織布、ポイントボンド不織布、スパンレース不織布、ニードルパンチ不織布、メルトブローン不織布、及びこれらの組み合わせ(例えば、SMS等)等が挙げられる。
上記吸収コアの構成要素としては、例えば、親水性繊維、例えば、粉砕パルプ、コットン等のセルロース、レーヨン、フィブリルレーヨン等の再生セルロース、アセテート、トリアセテート等の半合成セルロース、粒子状ポリマー、繊維状ポリマー、熱可塑性疎水性化学繊維、及び親水化処理された熱可塑性疎水性化学繊維、並びにこれらの組み合わせ等が挙げられる。また、上記吸収コアの構成要素として、高吸収性ポリマー、例えば、アクリル酸ナトリウムコポリマー等の粒状物が挙げられる。
また、上記血液改質剤は、トップシートの平面方向に関しては、トップシートの全面、膣口付近の中心領域等、任意の場所に存在することができる。
また、中高部が上記血液改質剤を含む実施形態において、上記血液改質剤は、吸収した血液に迅速に移行するために、その表面積が大きいことが好ましく、液滴状又は粒子状で存在する血液改質剤は、粒径が小さいことが好ましい。
[製造例1]
トップシートとして、ポリエチレン(PE)の鞘と、ポリエチレンテレフタレート(PET)の芯とから形成された芯鞘構造を有し、親水処理された複合繊維(繊度:2.8dtexの)から成るエアスルー不織布(坪量:30g/m2)を準備した。
バックシートとして、PEを含むフィルム(坪量:23g/m2)の片面に、接着剤が塗布されたものを準備した。
クッション部を構成するエアスルー不織布の平均坪量を、下記表2に記載されるとおりに変更した以外は、製造例1に従って、吸収性物品No.1-2~No.1-8を製造した。
吸収性物品No.1-2~No.1-8の圧縮力を下記表2に併せて示す。
吸収性物品No.1-1~No.1-8を、それぞれ、複数枚準備し、複数の被験者に着用してもらい、下記の基準に従って、折り曲がり性と、吸収性物品が折り曲がった状態からの回復性とを評価してもらった。
○:折り曲がり性及び回復性に問題なし。
×:折り曲がり性及び/又は回復性に問題があった。
結果を、下記表2に示す。
血液改質剤として、パナセート810s(日油株式会社製、グリセリンと脂肪酸とのトリエステル)を選択し、吸収性物品No.1-4の中高部を中心に、室温において、コントロールシームHMAガンから5.0g/m2の坪量で、パナセート810sを塗工することにより、吸収性物品No.2-1を製造した。電子顕微鏡で確認したところ、パナセート810sは、微粒子状で、中高部のトップシートの繊維の表面に付着していた。
吸収性物品No.1-4を10名の被験者に着用してもらったところ、計20回の試験において、漏れが少ないとの回答を得た。また、ドライ時と、ウェット時との両方において、脚の動きに追従して変形し、フィット性に優れるとの回答を得た。
次いで、吸収性物品No.2-1を10名の被験者に着用してもらったところ、延べ20回の試験において、吸収性物品No.1-4と比較して、表面汚れの面積が少なく且つ漏れも少ないとの回答を得た。
[その他の血液改質剤のデータ]
市販の生理用ナプキンを準備した。当該生理用ナプキンは、親水剤で処理されたエアスルー不織布(ポリエステル及びポリエチレンテレフタレートから成る複合繊維、坪量:35g/m2)から形成されたトップシートと、エアスルー不織布(ポリエステル及びポリエチレンテレフタレートから成る複合繊維、坪量:30g/m2)から形成されたセカンドシートと、パルプ(坪量:150~450g/m2、中央部ほど多い)、アクリル系高吸収ポリマー(坪量:15g/m2)及びコアラップとしてのティッシュを含む吸収体と、撥水剤処理されたサイドシートと、ポリエチレンフィルムから成るバックシートとから形成されていた。
[(a1)鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステル]
・ユニスター H-408BRS,日油株式会社製
テトラ2-エチルヘキサン酸ペンタエリトリトール,重量平均分子量:約640
・ユニスター H-2408BRS-22,日油株式会社製
テトラ2-エチルヘキサン酸ペンタエリトリトールと、ジ2-エチルヘキサン酸ネオペンチルグリコールとの混合物(58:42,質量比),重量平均分子量:約520
・Cetiol SB45DEO,コグニスジャパン株式会社製
脂肪酸が、オレイン酸又はステアリル酸である、グリセリンと脂肪酸とのトリエステル
・SOY42,日油株式会社製
C14の脂肪酸:C16の脂肪酸:C18の脂肪酸:C20の脂肪酸(飽和脂肪酸及び不飽和脂肪酸の両方を含む)がおおよそ0.2:11:88:0.8の質量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:880
C8の脂肪酸:C10の脂肪酸:C12の脂肪酸がおおよそ37:7:56の質量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約570
・トリCL油脂肪酸グリセリド,日油株式会社製
C8の脂肪酸:C12の脂肪酸がおおよそ44:56の質量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約570
C8の脂肪酸:C10の脂肪酸がおおよそ85:15の質量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約480
・パナセート800,日油株式会社製
脂肪酸が全てオクタン酸(C8)である、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約470
脂肪酸が全て2-エチルヘキサン酸(C8)である、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約470
・NA36,日油株式会社製
C16の脂肪酸:C18の脂肪酸:C20の脂肪酸(飽和脂肪酸及び不飽和脂肪酸の両方を含む)がおおよそ5:92:3の質量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約880
C8の脂肪酸:C10の脂肪酸:C12の脂肪酸:C14の脂肪酸:C16の脂肪酸(飽和脂肪酸及び不飽和脂肪酸の両方を含む)がおおよそ4:8:60:25:3の質量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:670
・カプリル酸ジグリセリド,日油株式会社製
脂肪酸がオクタン酸である、グリセリンと脂肪酸とのジエステル,重量平均分子量:340
・コムポールBL,日油株式会社製
ブチレングリコールのドデカン酸(C12)モノエステル,重量平均分子量:約270
・コムポールBS,日油株式会社製
ブチレングリコールのオクタデカン酸(C18)モノエステル,重量平均分子量:約350
・ユニスター H-208BRS,日油株式会社製
ジ2-エチルヘキサン酸ネオペンチルグリコール,重量平均分子量:約360
・O-アセチルクエン酸トリブチル,東京化成工業株式会社製
重量平均分子量:約400
・アジピン酸ジオクチル,和光純薬工業製
重量平均分子量:約380
・エレクトールWE20,日油株式会社製
ドデカン酸(C12)と、ドデシルアルコール(C12)とのエステル,重量平均分子量:約360
・エレクトールWE40,日油株式会社製
テトラデカン酸(C14)と、ドデシルアルコール(C12)とのエステル,重量平均分子量:約390
・ユニオールD-1000,日油株式会社製
ポリプロピレングリコール,重量平均分子量:約1,000
・ユニオールD-1200,日油株式会社製
ポリプロピレングリコール,重量平均分子量:約1,200
・ユニオールD-3000,日油株式会社製
ポリプロピレングリコール,重量平均分子量:約3,000
ポリプロピレングリコール,重量平均分子量:約4,000
・ユニオールPB500,日油株式会社製
ポリブチレングリコール,重量平均分子量:約500
・ユニオールPB700,日油株式会社製
ポリオキシブチレンポリオキシプロピレングリコール,重量平均分子量:約700
ポリブチレングリコール,重量平均分子量:約1000
[(e2)ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪酸とのエステル]
・ウィルブライトcp9,日油株式会社製
ポリブチレングリコールの両末端のOH基が、ヘキサデカン酸(C16)によりエステル化された化合物,重量平均分子量:約1,150
・ユニルーブMS-70K,日油株式会社製
ポリプロピレングリコールのステアリルエーテル,約15の繰返し単位,重量平均分子量:約1,140
・ユニルーブ5TP-300KB
ペンタエリトリトール1モルに、エチレンオキシド5モルと、プロピレンオキシド65モルとを付加させることにより生成した、ポリオキシエチレンポリオキシプロピレンペンタエリスリトールエーテル,重量平均分子量:4,130
ポリプロピレングリコールのグリセリルエーテル,約16の繰返し単位,重量平均分子量:約3,000
・ユニオール TG-4000,日油株式会社製
ポリプロピレングリコールのグリセリルエーテル,約16の繰返し単位,重量平均分子量:約4,000
・パールリーム6,日油株式会社製
流動イソパラフィン、イソブテン及びn-ブテンを共重合し、次いで水素を付加することにより生成された分岐鎖炭化水素、重合度:約5~約10,重量平均分子量:約330
・NA50,日油株式会社製
NA36に水素を付加し、原料である不飽和脂肪酸に由来する二重結合の比率を下げたグリセリンと脂肪酸とのトリエステル,重量平均分子量:約880
・(カプリル酸/カプリン酸)モノグリセリド,日油株式会社製
オクタン酸(C8)及びデカン酸(C10)がおおよそ85:15の質量比で含まれている、グリセリンと脂肪酸とのモノエステル,重量平均分子量:約220
・Monomuls 90-L2ラウリン酸モノグリセリド,コグニスジャパン株式会社製
重量平均分子量:約230
・リンゴ酸ジイソステアリル
重量平均分子量:約640
・ユニオールD-400,日油株式会社製
ポリプロピレングリコール,重量平均分子量:約400
ポリエチレングリコール,重量平均分子量:約1,500~約1,600
・ノニオンS-6,日油株式会社製
ポリオキシエチレンモノステアレート、約7の繰返し単位、重量平均分子量:約880
・ウィルブライトs753,日油株式会社製
ポリオキシエチレンポリオキシプロピレンポリオキシブチレングリセリン,重量平均分子量:約960
ポリプロピレングリコールのグリセリルエーテル,約6の繰返し単位,重量平均分子量:約330
・ユニオール TG-1000,日油株式会社製
ポリプロピレングリコールのグリセリルエーテル,約16の繰返し単位,重量平均分子量:約1,000
ポリプロピレングリコールのジグリセリルエーテル,約9の繰返し単位,重量平均分子量:約700
・ユニオックスHC60,日油株式会社製
ポリオキシエチレン硬化ヒマシ油,重量平均分子量:約3,570
・ワセリン,コグニスジャパン株式会社製
石油に由来する炭化水素、半固形
なお、水溶解度は、上述の方法に従って測定したが、100gの脱塩水に、20.0gを添加し、24時間後に溶解した試料は、「20g<」と評価し、そして100gの脱塩水に、0.05gは溶解したが、1.00gは溶解しなかった試料は、0.05~1.00gと評価した。
また、融点に関し、「<45」は、融点が45℃未満であることを意味する。
各血液改質剤を含むトップシートの上に、穴の開いたアクリル板(200mm×100mm,125g,中央に、40mm×10mmの穴が開いている)を置き、上記穴から、37±1℃のウマEDTA血(ウマの血液に、凝結防止のため、エチレンジアミン四酢酸(以下、「EDTA」と称する)が添加されたもの)3gを、ピペットを用いて滴下(1回目)し、1分後、37±1℃のウマEDTA血3gを、アクリル板の穴から、ピペットで再度滴下した(2回目)。
リウェット率(%)=100×(試験後のろ紙質量-当初のろ紙質量)/6
リウェット率と、吸収体移行速度の結果を、以下の表3に示す。
◎:血液の赤さがほとんど残っておらず、血液が存在した場所と、存在していない場所との区別がつかない
○:血液の赤さが若干残っているが、血液の存在した場所と、存在していない場所との区別がつきいにくい
△:血液の赤さが若干残っており、血液が存在した場所が分かる
×:血液の赤さがそのまま残っている
結果を、併せて下記表3に示す。
動物の各種血液に関して、上述の手順に従って、リウェット率を評価した。実験に用いられた血液は、以下の通りである。
[動物種]
(1)ヒト
(2)ウマ
(3)ヒツジ
・脱繊維血:血液を採取後、ガラスビーズと共に、三角フラスコ内で約5分間撹拌したもの
・EDTA血:静脈血65mLに、12%EDTA・2K生理食塩液0.5mLを添加したもの
血清又は血漿:それぞれ、脱繊維血又はEDTA血を、室温下で、約1900Gで10分間遠心分離した後の上清
血球:血液から血清を除去し、残差をリン酸緩衝生理食塩液(PBS)で2回洗浄し、次いで除去した血清分のリン酸緩衝生理食塩液を加えたもの
結果を、下記表4に示す。
[血液保持性の評価]
血液改質剤を含むトップシートと、血液改質剤を含まないトップシートとにおける血液保持性を評価した。
(1)エアスルー不織布(ポリエステル及びポリエチレンテレフタレートから成る複合繊維、坪量:35g/m2)から形成されたトップシートの肌当接面に、トリC2L油脂肪酸グリセリドを、コントロールシームHMAガンを用いて微粒化し、坪量がおおよそ5g/m2となるように塗布する。また、比較のため、トリC2L油脂肪酸グリセリドを塗布していないものも準備する。次いで、トリC2L油脂肪酸グリセリドが塗布されているトップシートと、塗布されていないトップシートとの両方を、0.2gの大きさにカットし、セルストレイナー+トップシートの質量(a)を正確に測定する。
(3)セルストレイナーを、遠心管にセットし、スピンダウンして、余剰のウマEDTA血を取り除く。
(4)セルストレイナー+ウマEDTA血を含むトップシートの質量(b)を測定する。
(5)下式に従って、トップシート1g当たりの当初吸収量(g)を算出する。
当初吸収量=[質量(b)-質量(a)]/0.2
(6)セルストレイナーを、遠心管に再セットし、室温下、約1200Gで1分間遠心分離する。
(8)下式に従って、トップシート1g当たりの試験後吸収量(g)を算出する。
試験後吸収量=[質量(c)-質量(a)]/0.2
(9)下式に従って血液保持率(%)を算出した。
血液保持率(%)=100×試験後吸収量/当初吸収量
なお、測定は3回行い、その平均値を採用した。
結果を、下記表5に示す。
[血液改質剤を含む血液の粘性]
血液改質剤を含む血液の粘性を、Rheometric Expansion System ARES(Rheometric Scientific,Inc)を用いて測定した。ウマ脱繊維血に、パナセート810sを2質量%添加し、軽く撹拌して試料を形成し、直径50mmのパラレルプレートに試料を載せ、ギャップを100μmとし、37±0.5℃で粘度を測定した。パラレルプレートゆえ、試料に均一なせん断速度はかかっていないが、機器に表示された平均せん断速度は、10s-1であった。
血液は、血球等の成分を含み、チキソトロピーの性質を有することが知られているが、本開示の血液改質剤は、低粘度域で、血液の粘度を下げることができることが示唆される。血液の粘度を下げることにより、吸収した経血を、トップシートから吸収体に速やかに移行させることができる。
[血液改質剤を含む血液の顕微鏡写真]
健常ボランティアの経血を食品保護用ラップフィルム上に採取し、その一部に、10倍の質量のリン酸緩衝生理食塩水中に分散されたパナセート810sを、パナセート810sの濃度が1質量%となるように添加した。経血を、スライドグラスに適下し、カバーグラスをかけ、光学顕微鏡にて、赤血球の状態を観察した。血液改質剤を含まない経血の顕微鏡写真を図11(a)に、そしてパナセート810sを含む経血の顕微鏡写真を図11(b)に示す。
[血液改質剤を含む血液の表面張力]
血液改質剤を含む血液の表面張力を、協和界面科学社製接触角計 Drop Master500を用い、ペンダントドロップ法にて測定した。表面張力は、ヒツジ脱繊維血に、所定の量の血液改質剤を添加し、十分振とうした後に測定した。
測定は、機器が自動で行うが、表面張力γは、以下の式により求められる(図12を参照)。
g:重力定数
1/H:ds/deから求められる補正項
ρ:密度
de:最大直径
ds:滴下端よりdeだけ上がった位置での径
測定には、京都電子工業株式会社のDA-505を用いた。
結果を、表6に示す。
血液の表面張力を下げることにより、吸収した血液をトップシートの繊維間に保持せず、速やかに吸収体に移行させることができる。
[J1]
液透過性のトップシートと、液不透過性のバックシートと、上記液透過性のトップシート及び液不透過性のバックシートの間の吸収体とを含む吸収性物品であって、
上記吸収性物品が、排泄口当接域に、上記吸収性物品の厚さ方向に突出する中高部を有し、
上記中高部が、上記トップシートの一部と、上記トップシート及び吸収体の間に配置されているクッション部とを含み、
上記クッション部が、3~30mmの最大厚さを有し、
上記吸収体が、上記吸収性物品の長手方向に、上記吸収体を連続的又は間欠的に圧搾することにより形成された、一又は複数の圧搾部を有し、そして
上記一又は複数の圧搾部が、上記吸収性物品を、その幅方向に且つ上記トップシートの肌当接面が突出するように折り曲げるための折り軸を形成している、
ことを特徴とする、上記吸収性物品。
上記クッション部が、50~800g/cm2の平均坪量を有する、J1に記載の吸収性物品。
[J3]
上記クッション部が、上記吸収性物品の幅方向において、0.1~3.6Nの圧縮力を有する、J1又はJ2に記載の吸収性物品。
上記クッション部が、各繊維の交点が熱融着されているエアスルー不織布を含む、J1~J3のいずれか一項に記載の吸収性物品。
[J5]
上記吸収体が、上記折り軸を形成する、上記一又は複数の圧搾部を、上記クッション部と厚さ方向に重複する範囲に有する、J1~J4のいずれか一項に記載の吸収性物品。
上記吸収体が、上記バックシート側に、上記折り軸に沿った溝部を有し、上記バックシートが、上記溝部に沿って窪んでいる、J1~J5のいずれか一項に記載の吸収性物品。
[J7]
上記中高部が、中央部と、当該中央部を囲む外周部とを有し、そして上記外周部におけるクッション部の密度が、上記中央部におけるクッション部の密度よりも高い、J1~J6のいずれか一項に記載の吸収性物品。
上記クッション部が、ウマEDTA血2gを吸収させた後に、ウマEDTA血を吸収させる前と比較して、50%以上の最大厚さを保持する、J1~J7のいずれか一項に記載の吸収性物品。
[J9]
上記吸収性物品が、上記中高部を内側に向けて湾曲する湾曲構造を有する、J1~J8のいずれか一項に記載の吸収性物品。
上記トップシートが、肌当接面に、上記吸収性物品の長手方向に延びる、複数の畝部と、複数の溝部とを有する、J1~J9のいずれか一項に記載の吸収性物品。
[J11]
上記中高部が、0.00~0.60のIOBと、45℃以下の融点と、25℃の水100gに対する、0.00~0.05gの水溶解度とを有する血液改質剤をさらに含む、J1~J10のいずれか一項に記載の吸収性物品。
上記血液改質剤が、次の(i)~(iii)、
(i)炭化水素、
(ii) (ii-1)炭化水素部分と、(ii-2)上記炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、及び
(iii) (iii-1)炭化水素部分と、(iii-2)上記炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基と、(iii-3)上記炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
並びにそれらの任意の組み合わせから成る群から選択され、
ここで、(ii)又は(iii)の化合物において、オキシ基が2つ以上挿入されている場合には、各オキシ基は隣接していない、
J11に記載の吸収性物品。
上記血液改質剤が、次の(i’)~(iii’)、
(i’)炭化水素、
(ii’) (ii’-1)炭化水素部分と、(ii’-2)上記炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合とを有する化合物、及び
(iii’) (iii’-1)炭化水素部分と、(iii’-2)上記炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合と、(iii’-3)上記炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
並びにそれらの任意の組み合わせから成る群から選択され、
ここで、(ii’)又は(iii’)の化合物において、2以上の同一又は異なる結合が挿入されている場合には、各結合は隣接していない、
J11又はJ12に記載の吸収性物品。
上記血液改質剤が、次の(A)~(F)、
(A) (A1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(A2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のカルボキシル基とを有する化合物とのエステル、
(B) (B1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(B2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエーテル、
(C) (C1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する、2~4個のカルボキシル基とを含むカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、(C2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエステル、
(D)鎖状炭化水素部分と、上記鎖状炭化水素部分のC-C単結合間に挿入された、エーテル結合(-O-)、カルボニル結合(-CO-)、エステル結合(-COO-)、及びカーボネート結合(-OCOO-)から成る群から選択されるいずれか1つの結合とを有する化合物、
(E)ポリオキシC2~C6アルキレングリコール、又はそのエステル若しくはエーテル、及び
(F)鎖状炭化水素、
並びにそれらの任意の組み合わせから成る群から選択される、J11~J13のいずれか一項に記載の吸収性物品。
上記血液改質剤が、(a1)鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステル、(a2)鎖状炭化水素トリオールと少なくとも1の脂肪酸とのエステル、(a3)鎖状炭化水素ジオールと少なくとも1の脂肪酸とのエステル、(b1)鎖状炭化水素テトラオールと少なくとも1の脂肪族1価アルコールとのエーテル、(b2)鎖状炭化水素トリオールと少なくとも1の脂肪族1価アルコールとのエーテル、(b3)鎖状炭化水素ジオールと少なくとも1の脂肪族1価アルコールとのエーテル、(c1)4個のカルボキシル基を有する鎖状炭化水素テトラカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(c2)3個のカルボキシル基を有する鎖状炭化水素トリカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(c3)2個のカルボキシル基を有する鎖状炭化水素ジカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(d1)脂肪族1価アルコールと脂肪族1価アルコールとのエーテル、(d2)ジアルキルケトン、(d3)脂肪酸と脂肪族1価アルコールとのエステル、(d4)ジアルキルカーボネート、(e1)ポリオキシC2~C6アルキレングリコール、(e2)ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪酸とのエステル、(e3)ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪族1価アルコールとのエーテル、(e4)ポリオキシC2~C6アルキレングリコールと、鎖状炭化水素テトラカルボン酸、鎖状炭化水素トリカルボン酸、又は鎖状炭化水素ジカルボン酸とのエステル、(e5)ポリオキシC2~C6アルキレングリコールと、鎖状炭化水素テトラオール、鎖状炭化水素トリオール、又は鎖状炭化水素ジオールとのエーテル、及び(f1)鎖状アルカン、並びにそれらの任意の組み合わせから成る群から選択される、J11~J14のいずれか一項に記載の吸収性物品。
2 中高部
3 圧搾部
4 トップシート
5 剥離部
6 クッション部
7 吸収体
8 バックシート
9 固定部
11 中央部
12 外周部
13 圧搾部
14 折り軸
15 弾性部材
16 溝部
21 圧縮力測定装置
22 スタンド
23 稼働台
24 デジタルフォースゲージ
25 試料台
26 試料
27 圧縮パーツ
28 ストッパー
Claims (15)
- 液透過性のトップシートと、液不透過性のバックシートと、前記液透過性のトップシート及び液不透過性のバックシートの間の吸収体とを含む吸収性物品であって、
前記吸収性物品が、排泄口当接域に、前記吸収性物品の厚さ方向に突出する中高部を有し、
前記中高部が、前記トップシートの一部と、前記トップシート及び吸収体の間に配置されているクッション部とを含み、
前記クッション部が、3~30mmの最大厚さを有し、
前記吸収体が、前記吸収性物品の長手方向に、前記吸収体を連続的又は間欠的に圧搾することにより形成された、一又は複数の圧搾部を有し、そして
前記一又は複数の圧搾部が、前記吸収性物品を、その幅方向に且つ前記トップシートの肌当接面が突出するように折り曲げるための折り軸を形成している、
ことを特徴とする、前記吸収性物品。 - 前記クッション部が、50~800g/cm2の平均坪量を有する、請求項1に記載の吸収性物品。
- 前記クッション部が、前記吸収性物品の幅方向において、0.1~3.6Nの圧縮力を有する、請求項1又は2に記載の吸収性物品。
- 前記クッション部が、各繊維の交点が熱融着されているエアスルー不織布を含む、請求項1~3のいずれか一項に記載の吸収性物品。
- 前記吸収体が、前記折り軸を形成する、前記一又は複数の圧搾部を、前記クッション部と厚さ方向に重複する範囲に有する、請求項1~4のいずれか一項に記載の吸収性物品。
- 前記吸収体が、前記バックシート側に、前記折り軸に沿った溝部を有し、前記バックシートが、前記溝部に沿って窪んでいる、請求項1~5のいずれか一項に記載の吸収性物品。
- 前記中高部が、中央部と、当該中央部を囲む外周部とを有し、そして前記外周部におけるクッション部の密度が、前記中央部におけるクッション部の密度よりも高い、請求項1~6のいずれか一項に記載の吸収性物品。
- 前記クッション部が、ウマEDTA血2gを吸収させた後に、ウマEDTA血を吸収させる前と比較して、50%以上の最大厚さを保持する、請求項1~7のいずれか一項に記載の吸収性物品。
- 前記吸収性物品が、前記中高部を内側に向けて湾曲する湾曲構造を有する、請求項1~8のいずれか一項に記載の吸収性物品。
- 前記トップシートが、肌当接面に、前記吸収性物品の長手方向に延びる、複数の畝部と、複数の溝部とを有する、請求項1~9のいずれか一項に記載の吸収性物品。
- 前記中高部が、0.00~0.60のIOBと、45℃以下の融点と、25℃の水100gに対する、0.00~0.05gの水溶解度とを有する血液改質剤をさらに含む、請求項1~10のいずれか一項に記載の吸収性物品。
- 前記血液改質剤が、次の(i)~(iii)、
(i)炭化水素、
(ii) (ii-1)炭化水素部分と、(ii-2)前記炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、及び
(iii) (iii-1)炭化水素部分と、(iii-2)前記炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基と、(iii-3)前記炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
並びにそれらの任意の組み合わせから成る群から選択され、
ここで、(ii)又は(iii)の化合物において、オキシ基が2つ以上挿入されている場合には、各オキシ基は隣接していない、
請求項11に記載の吸収性物品。 - 前記血液改質剤が、次の(i’)~(iii’)、
(i’)炭化水素、
(ii’) (ii’-1)炭化水素部分と、(ii’-2)前記炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合とを有する化合物、及び
(iii’) (iii’-1)炭化水素部分と、(iii’-2)前記炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合と、(iii’-3)前記炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
並びにそれらの任意の組み合わせから成る群から選択され、
ここで、(ii’)又は(iii’)の化合物において、2以上の同一又は異なる結合が挿入されている場合には、各結合は隣接していない、
請求項11又は12に記載の吸収性物品。 - 前記血液改質剤が、次の(A)~(F)、
(A) (A1)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(A2)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する1個のカルボキシル基とを有する化合物とのエステル、
(B) (B1)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(B2)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエーテル、
(C) (C1)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する、2~4個のカルボキシル基とを含むカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、(C2)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエステル、
(D)鎖状炭化水素部分と、前記鎖状炭化水素部分のC-C単結合間に挿入された、エーテル結合(-O-)、カルボニル結合(-CO-)、エステル結合(-COO-)、及びカーボネート結合(-OCOO-)から成る群から選択されるいずれか1つの結合とを有する化合物、
(E)ポリオキシC2~C6アルキレングリコール、又はそのエステル若しくはエーテル、及び
(F)鎖状炭化水素、
並びにそれらの任意の組み合わせから成る群から選択される、請求項11~13のいずれか一項に記載の吸収性物品。 - 前記血液改質剤が、(a1)鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステル、(a2)鎖状炭化水素トリオールと少なくとも1の脂肪酸とのエステル、(a3)鎖状炭化水素ジオールと少なくとも1の脂肪酸とのエステル、(b1)鎖状炭化水素テトラオールと少なくとも1の脂肪族1価アルコールとのエーテル、(b2)鎖状炭化水素トリオールと少なくとも1の脂肪族1価アルコールとのエーテル、(b3)鎖状炭化水素ジオールと少なくとも1の脂肪族1価アルコールとのエーテル、(c1)4個のカルボキシル基を有する鎖状炭化水素テトラカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(c2)3個のカルボキシル基を有する鎖状炭化水素トリカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(c3)2個のカルボキシル基を有する鎖状炭化水素ジカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(d1)脂肪族1価アルコールと脂肪族1価アルコールとのエーテル、(d2)ジアルキルケトン、(d3)脂肪酸と脂肪族1価アルコールとのエステル、(d4)ジアルキルカーボネート、(e1)ポリオキシC2~C6アルキレングリコール、(e2)ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪酸とのエステル、(e3)ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪族1価アルコールとのエーテル、(e4)ポリオキシC2~C6アルキレングリコールと、鎖状炭化水素テトラカルボン酸、鎖状炭化水素トリカルボン酸、又は鎖状炭化水素ジカルボン酸とのエステル、(e5)ポリオキシC2~C6アルキレングリコールと、鎖状炭化水素テトラオール、鎖状炭化水素トリオール、又は鎖状炭化水素ジオールとのエーテル、及び(f1)鎖状アルカン、並びにそれらの任意の組み合わせから成る群から選択される、請求項11~14のいずれか一項に記載の吸収性物品。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380018195.6A CN104244883B (zh) | 2012-03-30 | 2013-03-26 | 吸收性物品 |
SG11201404674YA SG11201404674YA (en) | 2012-03-30 | 2013-03-26 | Absorptive article |
EP13770073.8A EP2832331B1 (en) | 2012-03-30 | 2013-03-26 | Absorptive article |
US14/389,274 US9314383B2 (en) | 2012-03-30 | 2013-03-26 | Absorptive article |
AU2013241412A AU2013241412B2 (en) | 2012-03-30 | 2013-03-26 | Absorptive article |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012-081765 | 2012-03-30 | ||
JP2012081765A JP5726121B2 (ja) | 2012-03-30 | 2012-03-30 | 吸収性物品 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013146814A1 true WO2013146814A1 (ja) | 2013-10-03 |
Family
ID=49260065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/058855 WO2013146814A1 (ja) | 2012-03-30 | 2013-03-26 | 吸収性物品 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9314383B2 (ja) |
EP (1) | EP2832331B1 (ja) |
JP (1) | JP5726121B2 (ja) |
CN (1) | CN104244883B (ja) |
AR (1) | AR090527A1 (ja) |
AU (1) | AU2013241412B2 (ja) |
SG (1) | SG11201404674YA (ja) |
TW (1) | TWI597054B (ja) |
WO (1) | WO2013146814A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6057664B2 (ja) * | 2011-12-28 | 2017-01-11 | ユニ・チャーム株式会社 | 吸収性物品、及びその製造方法 |
JP6155296B2 (ja) * | 2015-03-31 | 2017-06-28 | ユニ・チャーム株式会社 | 吸収性物品 |
JP2018523556A (ja) * | 2015-07-31 | 2018-08-23 | ザ プロクター アンド ギャンブル カンパニー | 成形された不織布を用いた吸収性物品のパッケージ |
CN109196163B (zh) * | 2016-05-31 | 2022-03-11 | 花王株式会社 | 长纤维无纺布 |
US20190314217A1 (en) * | 2016-06-28 | 2019-10-17 | Essity Hygiene And Health Aktiebolag | Intimate skin conditioner veil comprising a nonwoven material |
US10835426B2 (en) * | 2016-08-12 | 2020-11-17 | Rebecca Coffman | Sanitary pad |
JP6439007B2 (ja) * | 2017-05-18 | 2018-12-19 | ユニ・チャーム株式会社 | 吸収性物品 |
JP2020524010A (ja) * | 2017-06-19 | 2020-08-13 | ティーラ ケア リミテッド | 女性用尿装置 |
CN111150559B (zh) * | 2018-11-08 | 2022-08-19 | 尤妮佳股份有限公司 | 吸收性物品 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002528174A (ja) | 1998-10-23 | 2002-09-03 | ザ、プロクター、エンド、ギャンブル、カンパニー | 選択的開閉自在開口を含むトップシートを有する吸収体 |
JP2003052750A (ja) * | 2001-08-10 | 2003-02-25 | Uni Charm Corp | 吸収性物品 |
JP2006115996A (ja) | 2004-10-20 | 2006-05-11 | Kao Corp | 吸収性物品 |
JP2008025079A (ja) | 2006-06-23 | 2008-02-07 | Uni Charm Corp | 不織布 |
JP2008025078A (ja) | 2006-06-23 | 2008-02-07 | Uni Charm Corp | 不織布 |
WO2008072675A1 (ja) * | 2006-12-13 | 2008-06-19 | Uni-Charm Corporation | 吸収性物品 |
JP2011067484A (ja) * | 2009-09-28 | 2011-04-07 | Kao Corp | 吸収性物品 |
JP2011226010A (ja) | 2010-04-16 | 2011-11-10 | Uni Charm Corp | 凹凸を有する不織布を簡易に製造する方法、及び不織布を簡易に加工する方法 |
JP2011226011A (ja) | 2010-04-16 | 2011-11-10 | Uni Charm Corp | 伸長性繊維と伸縮性繊維とを含む、凹凸を有する不織布、及び当該不織布を製造する方法 |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US604380A (en) * | 1898-05-24 | Wagon-brake | ||
US122014A (en) * | 1871-12-19 | Improvement in projectiles | ||
US3929135A (en) | 1974-12-20 | 1975-12-30 | Procter & Gamble | Absorptive structure having tapered capillaries |
JPS5717081A (en) | 1981-05-25 | 1982-01-28 | Noriko Ikegami | Electronic interpreter |
US4588630A (en) | 1984-06-13 | 1986-05-13 | Chicopee | Apertured fusible fabrics |
JPH0775616B2 (ja) | 1987-07-30 | 1995-08-16 | 花王株式会社 | 衛生用品の表面材 |
ES2065900T3 (es) | 1987-07-30 | 1995-03-01 | Kao Corp | Articulo sanitario. |
US4759754A (en) | 1987-08-26 | 1988-07-26 | Personal Products Company | Sanitary napkin |
JPH082364B2 (ja) | 1987-12-16 | 1996-01-17 | 花王株式会社 | 衛生用品の表面材 |
JPH0720856B2 (ja) | 1988-12-01 | 1995-03-08 | 株式会社大塚製薬工場 | 皮膚の殺菌・清拭用組成物 |
JP2728921B2 (ja) | 1989-03-01 | 1998-03-18 | 花王株式会社 | 凹凸を有する不織布の製造方法 |
US5334176A (en) | 1991-07-23 | 1994-08-02 | The Procter & Gamble Company | Absorbent core for use in catamenial products |
HU215632B (hu) | 1991-07-23 | 1999-01-28 | Procter And Gamble Co. | Hajlított formájú abszorbens cikk |
MA22660A1 (fr) | 1991-10-01 | 1993-04-01 | Procter & Gamble | Article absorbant comportant des rabats et des zones d'extensibilite differentielle . |
JP3091283B2 (ja) | 1991-12-09 | 2000-09-25 | 花王株式会社 | 生理用ナプキン |
JPH065614A (ja) | 1992-06-17 | 1994-01-14 | Murata Mfg Co Ltd | 熱処理装置 |
JPH08510665A (ja) | 1993-05-21 | 1996-11-12 | ザ、プロクター、エンド、ギャンブル、カンパニー | 染み透り阻止用圧着接合部を有する吸収物品 |
JPH0784697A (ja) | 1993-09-10 | 1995-03-31 | Canon Inc | 情報処理装置 |
US5614283A (en) | 1994-12-22 | 1997-03-25 | Tredegar Industries | Absorbent composite with three-dimensional film surface for use in absorbent disposable products |
JP2974934B2 (ja) | 1995-06-02 | 1999-11-10 | ザ、プロクター、エンド、ギャンブル、カンパニー | 生理用ナプキン |
US5650214A (en) | 1996-05-31 | 1997-07-22 | The Procter & Gamble Company | Web materials exhibiting elastic-like behavior and soft, cloth-like texture |
US5891126A (en) | 1996-08-30 | 1999-04-06 | The Procter & Gamble Company | Absorbent interlabial device treated with a polysiloxane emollient |
JPH1095810A (ja) | 1996-09-24 | 1998-04-14 | Oji Paper Co Ltd | 高吸水性樹脂及びその製造方法 |
ZA985679B (en) | 1997-06-30 | 1999-01-26 | Procter & Gamble | Absorbent article with multi-layered extensible wings |
DE69724667T2 (de) | 1997-12-05 | 2004-06-24 | The Procter & Gamble Company, Cincinnati | Zusammengesetzte damenbinde mit flügeln und ausdehnungszonen |
US6730819B1 (en) | 1999-03-05 | 2004-05-04 | The Procter & Gamble Company | Articles comprising oxidizing and hemolytic agents |
EP1034804A1 (en) | 1999-03-05 | 2000-09-13 | The Procter & Gamble Company | Articles comprising an oxidising agent and a hemolytic agent |
US6153209A (en) | 1999-09-28 | 2000-11-28 | The Procter & Gamble Company | Article having a transferable breathable skin care composition thereon |
JP3748743B2 (ja) | 1999-10-04 | 2006-02-22 | ユニ・チャーム株式会社 | 吸収性物品およびその製造方法 |
JP3611761B2 (ja) | 1999-11-02 | 2005-01-19 | 花王株式会社 | 吸収性物品 |
US20010044614A1 (en) | 1999-12-23 | 2001-11-22 | Damay Emmanuelle Cecile | Reducing agents for feminine care products |
JP3701208B2 (ja) | 2000-03-13 | 2005-09-28 | ユニ・チャーム株式会社 | 開孔シートとこの開孔シートを使用した吸収性物品および前記開孔シートの製造方法。 |
EP1250940B1 (en) | 2001-04-17 | 2010-01-06 | The Procter & Gamble Company | An absorbent article comprising an agent able to convey a perception to the wearer |
JP3922895B2 (ja) * | 2001-06-29 | 2007-05-30 | ユニ・チャーム株式会社 | 生理用ナプキン |
JP3926587B2 (ja) | 2001-07-12 | 2007-06-06 | ユニ・チャーム株式会社 | 吸収性物品 |
SE519783C2 (sv) | 2001-08-31 | 2003-04-08 | Sca Hygiene Prod Ab | Absorberande alster innefattande öppningar i absorptionskroppen |
US20030082219A1 (en) | 2001-10-01 | 2003-05-01 | The Procter & Gamble Company | Skin care compositions comprising low concentrations of skin treatment agents |
SG103382A1 (en) | 2002-01-11 | 2004-04-29 | Uni Charm Corp | Colored absorbent article |
JP4693847B2 (ja) | 2002-03-26 | 2011-06-01 | ユニ・チャーム株式会社 | 吸収性物品およびその製造方法 |
JP4278963B2 (ja) | 2002-03-26 | 2009-06-17 | ユニ・チャーム株式会社 | 吸収性物品 |
DE60231704D1 (de) | 2002-06-12 | 2009-05-07 | Sca Hygiene Prod Ab | Absorbierender Artikel mit einer Hautpflegezusammensetzung |
JP3949020B2 (ja) | 2002-07-19 | 2007-07-25 | 花王株式会社 | 吸収性物品 |
US9035123B2 (en) | 2002-10-01 | 2015-05-19 | The Procter & Gamble Company | Absorbent article having a lotioned topsheet |
US8030535B2 (en) | 2002-12-18 | 2011-10-04 | The Procter & Gamble Company | Sanitary napkin for clean body benefit |
JP2005095759A (ja) | 2003-09-24 | 2005-04-14 | San-Dia Polymer Ltd | 吸収剤とこれを用いてなる吸収性物品 |
US20050096614A1 (en) | 2003-10-29 | 2005-05-05 | Perez Roberto C. | Cover layer for an absorbent article |
JP4476102B2 (ja) | 2003-12-11 | 2010-06-09 | 花王株式会社 | 吸収性物品の表面シート |
HUE032039T2 (en) | 2004-06-21 | 2017-10-30 | Procter & Gamble | Absorbent product with a semi-solid medium top layer |
JP4683892B2 (ja) * | 2004-09-30 | 2011-05-18 | ユニ・チャーム株式会社 | 吸収性パッド |
US8211078B2 (en) | 2005-02-17 | 2012-07-03 | The Procter And Gamble Company | Sanitary napkins capable of taking complex three-dimensional shape in use |
JP4870365B2 (ja) * | 2005-02-23 | 2012-02-08 | ユニ・チャーム株式会社 | 生理用ナプキン |
JP4514630B2 (ja) | 2005-03-16 | 2010-07-28 | 花王株式会社 | 吸収性物品の表面シート |
JP4523866B2 (ja) | 2005-03-31 | 2010-08-11 | ユニ・チャーム株式会社 | 吸収性物品 |
EP1885315A1 (en) | 2005-06-02 | 2008-02-13 | The Procter and Gamble Company | Absorbent article having traverse reinforcing element |
JP4792249B2 (ja) | 2005-07-11 | 2011-10-12 | ユニ・チャーム株式会社 | 体液吸収性物品 |
CN101400329B (zh) | 2006-03-14 | 2014-02-19 | 宝洁公司 | 具有洗剂的吸收制品 |
JP5069891B2 (ja) | 2006-06-23 | 2012-11-07 | ユニ・チャーム株式会社 | 不織布 |
JP5328113B2 (ja) | 2006-06-23 | 2013-10-30 | ユニ・チャーム株式会社 | 吸収性物品 |
JP5154048B2 (ja) | 2006-06-23 | 2013-02-27 | ユニ・チャーム株式会社 | 不織布 |
JP5328089B2 (ja) | 2006-06-23 | 2013-10-30 | ユニ・チャーム株式会社 | 多層不織布及び多層不織布の製造方法 |
JP5069890B2 (ja) | 2006-06-23 | 2012-11-07 | ユニ・チャーム株式会社 | 不織布 |
JP5328088B2 (ja) | 2006-06-23 | 2013-10-30 | ユニ・チャーム株式会社 | 不織布 |
JP5123513B2 (ja) | 2006-06-23 | 2013-01-23 | ユニ・チャーム株式会社 | 吸収体 |
JP5123497B2 (ja) | 2006-06-23 | 2013-01-23 | ユニ・チャーム株式会社 | 不織布、不織布製造方法及び不織布製造装置 |
JP5123512B2 (ja) | 2006-06-23 | 2013-01-23 | ユニ・チャーム株式会社 | 不織布 |
CN101484111B (zh) | 2006-07-05 | 2013-05-22 | 花王株式会社 | 吸收性物品 |
JP4986673B2 (ja) | 2007-03-27 | 2012-07-25 | 花王株式会社 | 吸収性物品 |
JP5021380B2 (ja) | 2006-07-05 | 2012-09-05 | 花王株式会社 | 吸収性物品 |
JP4749288B2 (ja) | 2006-09-06 | 2011-08-17 | 花王株式会社 | 吸収性物品 |
US8998871B2 (en) * | 2006-11-22 | 2015-04-07 | Uni-Charm Corporation | Absorbent article with compressed channel portions |
JP4939196B2 (ja) | 2006-12-12 | 2012-05-23 | ユニ・チャーム株式会社 | 不織布、不織布の製造方法及び吸収性物品 |
ATE528425T1 (de) | 2006-12-05 | 2011-10-15 | Uni Charm Corp | Vliesstoff, verfahren zur herstellung von vliesstoff sowie saugkörper |
JP4939192B2 (ja) | 2006-12-05 | 2012-05-23 | ユニ・チャーム株式会社 | 不織布、不織布の製造方法及び吸収性物品 |
AR065378A1 (es) | 2007-02-16 | 2009-06-03 | Procter & Gamble | Articulo absorbente con locion que comprende un material de polipropilenglicol |
JP4979424B2 (ja) | 2007-03-20 | 2012-07-18 | 花王株式会社 | 吸収性物品 |
JP4979423B2 (ja) | 2007-03-20 | 2012-07-18 | 花王株式会社 | 吸収性物品 |
EP2138614A4 (en) | 2007-04-17 | 2011-03-30 | Uni Charm Corp | NONWOVEN FABRIC, PROCESS FOR PRODUCING NONWOVEN FABRIC, AND ABSORBENT ARTICLE |
JP4879074B2 (ja) | 2007-04-17 | 2012-02-15 | ユニ・チャーム株式会社 | 不織布製造方法 |
JP5114087B2 (ja) | 2007-04-17 | 2013-01-09 | ユニ・チャーム株式会社 | 不織布、及び、吸収性物品 |
ATE515275T1 (de) | 2007-05-15 | 2011-07-15 | Procter & Gamble | Verwendung einer lotionszusammensetzung auf einem saugfähigen artikel zur reduktion von fäkal- oder mensesanhaftung an der haut |
JP5161491B2 (ja) | 2007-05-30 | 2013-03-13 | ユニ・チャーム株式会社 | 吸収性物品 |
JP5568210B2 (ja) | 2007-06-13 | 2014-08-06 | ユニ・チャーム株式会社 | 不織布シートの製造方法 |
JP5497987B2 (ja) | 2007-06-22 | 2014-05-21 | ユニ・チャーム株式会社 | 不織布およびその製造方法 |
JP4652387B2 (ja) | 2007-10-03 | 2011-03-16 | 王子製紙株式会社 | 折り返し部を有する吸収体製品 |
CN101474112B (zh) * | 2008-01-02 | 2013-09-18 | 金佰利(中国)有限公司 | 具有沟道的吸湿性物品 |
CA2715577A1 (en) | 2008-02-15 | 2009-08-20 | The Proctor & Gamble Company | Absorbent article with lotion comprising a polypropylene glycol material |
JP2009201878A (ja) | 2008-02-29 | 2009-09-10 | Uni Charm Corp | 吸収性物品 |
JP5173616B2 (ja) | 2008-06-10 | 2013-04-03 | 花王株式会社 | 吸収性物品 |
JP5371361B2 (ja) | 2008-10-10 | 2013-12-18 | ユニ・チャーム株式会社 | 吸収性物品及び吸収性物品の製造方法 |
JP5455363B2 (ja) | 2008-12-25 | 2014-03-26 | ユニ・チャーム株式会社 | 薄型吸収性物品 |
JP5520124B2 (ja) | 2009-05-14 | 2014-06-11 | ユニ・チャーム株式会社 | 透液性繊維不織布 |
JP5401177B2 (ja) | 2009-06-04 | 2014-01-29 | 花王株式会社 | 吸収性物品 |
RU2555615C2 (ru) | 2009-05-20 | 2015-07-10 | Као Корпорейшн | Абсорбирующее тело и абсорбирующее изделие |
JP5590834B2 (ja) | 2009-08-11 | 2014-09-17 | ユニ・チャーム株式会社 | 不織布およびその製造方法 |
JP5623052B2 (ja) | 2009-09-29 | 2014-11-12 | ユニ・チャーム株式会社 | 不織布の製造方法 |
JP5328591B2 (ja) * | 2009-09-30 | 2013-10-30 | ユニ・チャーム株式会社 | 吸収性物品及び吸収性物品の製造装置 |
JP5530693B2 (ja) | 2009-09-30 | 2014-06-25 | 大王製紙株式会社 | 吸収性物品 |
JP5421720B2 (ja) | 2009-10-09 | 2014-02-19 | ユニ・チャーム株式会社 | 不織布 |
JP5395630B2 (ja) | 2009-11-13 | 2014-01-22 | 花王株式会社 | 吸収性物品 |
JP5466489B2 (ja) | 2009-11-16 | 2014-04-09 | 花王株式会社 | 吸収性物品 |
JP5551926B2 (ja) | 2009-12-09 | 2014-07-16 | 花王株式会社 | 吸収性物品 |
JP5538943B2 (ja) * | 2010-02-19 | 2014-07-02 | ユニ・チャーム株式会社 | 不織布シートおよびその製造方法 |
JP5649313B2 (ja) * | 2010-02-26 | 2015-01-07 | ユニ・チャーム株式会社 | 吸収性物品及び吸収性物品の製造方法 |
JP5749907B2 (ja) | 2010-08-31 | 2015-07-15 | ユニ・チャーム株式会社 | 吸収性物品及び生理用ナプキン |
TWI448277B (zh) | 2011-03-31 | 2014-08-11 | Uni Charm Corp | Absorbent items |
-
2012
- 2012-03-30 JP JP2012081765A patent/JP5726121B2/ja active Active
-
2013
- 2013-03-26 AU AU2013241412A patent/AU2013241412B2/en not_active Ceased
- 2013-03-26 SG SG11201404674YA patent/SG11201404674YA/en unknown
- 2013-03-26 WO PCT/JP2013/058855 patent/WO2013146814A1/ja active Application Filing
- 2013-03-26 US US14/389,274 patent/US9314383B2/en not_active Expired - Fee Related
- 2013-03-26 CN CN201380018195.6A patent/CN104244883B/zh active Active
- 2013-03-26 EP EP13770073.8A patent/EP2832331B1/en not_active Not-in-force
- 2013-03-27 AR ARP130101009A patent/AR090527A1/es unknown
- 2013-03-29 TW TW102111510A patent/TWI597054B/zh not_active IP Right Cessation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002528174A (ja) | 1998-10-23 | 2002-09-03 | ザ、プロクター、エンド、ギャンブル、カンパニー | 選択的開閉自在開口を含むトップシートを有する吸収体 |
JP2003052750A (ja) * | 2001-08-10 | 2003-02-25 | Uni Charm Corp | 吸収性物品 |
JP2006115996A (ja) | 2004-10-20 | 2006-05-11 | Kao Corp | 吸収性物品 |
JP2008025079A (ja) | 2006-06-23 | 2008-02-07 | Uni Charm Corp | 不織布 |
JP2008025078A (ja) | 2006-06-23 | 2008-02-07 | Uni Charm Corp | 不織布 |
WO2008072675A1 (ja) * | 2006-12-13 | 2008-06-19 | Uni-Charm Corporation | 吸収性物品 |
JP2011067484A (ja) * | 2009-09-28 | 2011-04-07 | Kao Corp | 吸収性物品 |
JP2011226010A (ja) | 2010-04-16 | 2011-11-10 | Uni Charm Corp | 凹凸を有する不織布を簡易に製造する方法、及び不織布を簡易に加工する方法 |
JP2011226011A (ja) | 2010-04-16 | 2011-11-10 | Uni Charm Corp | 伸長性繊維と伸縮性繊維とを含む、凹凸を有する不織布、及び当該不織布を製造する方法 |
Non-Patent Citations (2)
Title |
---|
FUJITA A.: "Organic compound predictions and organic paradigms", KAGAKU NO RYOIKI, vol. 11, no. 10, 1957, pages 719 - 725 |
See also references of EP2832331A4 |
Also Published As
Publication number | Publication date |
---|---|
EP2832331B1 (en) | 2017-11-29 |
SG11201404674YA (en) | 2014-10-30 |
US20150073370A1 (en) | 2015-03-12 |
AU2013241412B2 (en) | 2017-06-29 |
JP5726121B2 (ja) | 2015-05-27 |
AR090527A1 (es) | 2014-11-19 |
JP2013208361A (ja) | 2013-10-10 |
CN104244883A (zh) | 2014-12-24 |
TWI597054B (zh) | 2017-09-01 |
EP2832331A1 (en) | 2015-02-04 |
US9314383B2 (en) | 2016-04-19 |
AU2013241412A1 (en) | 2014-10-16 |
TW201402085A (zh) | 2014-01-16 |
EP2832331A4 (en) | 2015-08-26 |
CN104244883B (zh) | 2016-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6057664B2 (ja) | 吸収性物品、及びその製造方法 | |
JP5122007B1 (ja) | 吸収性物品 | |
JP5726121B2 (ja) | 吸収性物品 | |
JP5925015B2 (ja) | 吸収性物品 | |
JP5726120B2 (ja) | 吸収性物品 | |
JP5717686B2 (ja) | 吸収性物品 | |
WO2013129236A1 (ja) | 吸収性物品 | |
JP5745487B2 (ja) | 吸収性物品 | |
WO2014050767A1 (ja) | 吸収性物品 | |
JP5847055B2 (ja) | 吸収性物品 | |
JP5717685B2 (ja) | 吸収性物品 | |
JP6092508B2 (ja) | 吸収性物品 | |
JP6037606B2 (ja) | 吸収性物品、吸収性物品のトップシートおよびそのトップシートの製造方法 | |
JP5709788B2 (ja) | 吸収性物品 | |
JP5963639B2 (ja) | 吸収性物品 | |
JP2013208419A (ja) | 吸収性物品 | |
JP5769655B2 (ja) | 吸収性物品 | |
JP5762346B2 (ja) | 吸収性物品 | |
JP2017109125A (ja) | 吸収性物品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13770073 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2013770073 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013770073 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201405500 Country of ref document: ID |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14389274 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2013241412 Country of ref document: AU Date of ref document: 20130326 Kind code of ref document: A |